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ABSTRACT 
 
Evaluation of the Gastrointestinal Microbiota in Response to Dietary and Therapeutic 
Factors in Cats and Dogs Using Molecular Methods. (December 2011)  
Jose Francisco Garcia-Mazcorro, M.V.Z, Universidad Autonoma de Nuevo Leon 
Chair of Advisory Committee: Dr. Jan S. Suchodolski 
 
The gastrointestinal (GI) tract of cats and dogs is inhabited by many different types of 
microorganisms, known as the GI microbiota. Mounting evidence suggests that the 
administration of certain dietary and/or therapeutic agents can alter the composition and 
activity of the GI microbiota, thus influencing gastrointestinal health and disease. The 
aim of this study was to evaluate the gastrointestinal microbiota in response to dietary 
and therapeutic interventions in cats and dogs. A multi-species synbiotic formulation, 
containing a total of 5x109 colony forming units of a mixture of seven probiotic bacterial 
strains and a blend of prebiotics, was administered daily for 21 days to healthy cats and 
dogs. Fecal samples were collected before, during, and up to three weeks after 
discontinuation of the administration of the synbiotic. The fecal microbiota was analyzed 
using 454-pyrosequencing, denaturing gradient gel electrophoresis, quantitative real-
time PCR, and 16S rRNA gene clone libraries. The results showed that the synbiotic led 
to increased concentrations of probiotic bacteria in the feces but did not alter the 
predominant bacterial phyla. Additionally, we investigated the effect of age, body 
weight, and baseline abundance of probiotic related bacterial genera, as potential 
 iv
predictors of intestinal colonization by the ingested microorganisms. The results 
suggested that cats having a low abundance of fecal probiotic genera before consuming 
probiotics may have a higher concentration of the probiotic groups in feces during 
consumption of the synbiotic formulation. Also, a proton-pump inhibitor, aimed at 
suppressing the secretion of gastric acid, was administered daily for 15 days to healthy 
dogs. Changes in the GI microbiota were analyzed using 454-pyrosequencing, 
fluorescent in situ hybridization, and quantitative real-time PCR. The results suggested 
that inhibition of gastric acid secretion can alter the abundance of several gastric, 
duodenal, and fecal bacterial groups. However, these changes were not associated with 
major qualitative modifications of the overall composition of the GI microbiota. These 
studies showed that dietary and therapeutic agents can alter the composition of the GI 
microbiota and suggest that these changes could be associated with particular 
characteristics of the host. The clinical significance of these results needs further 
investigation.  
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1. INTRODUCTION 
 
1.1 The gastrointestinal microbiota 
The gastrointestinal (GI) tract of cats and dogs as well as other mammals is a long 
muscular canal extending from the mouth to the anus where assimilation of nutrients 
takes place. Perhaps due in part to the continuous supply and variety of nutrients, the GI 
tract of mammals is one of the most heavily populated microbial ecosystems known (Xu 
& Gordon, 2003; Ley et al., 2006). For example, a recent estimation of the cultivable 
fraction of the human GI microbiota included 442 bacterial, three archaeal, and 17 
eukaryotic species (Rajilic-Stojanovic, 2007). However, the GI tract may harbor more 
than 1,200 distinct microorganisms, most of which have yet to be cultured successfully 
(Rajilic-Stojanovic et al., 2007). Despite the presence of other types of microorganisms, 
bacteria make up the most abundant and functionality diverse microbial group in the GI 
tract of mammals. 
 
1.2 Characterization of the GI microbiota 
1.2.1 Culture methods 
Traditional culture methods for the identification of bacteria rely on phenotypic 
characterization, including the assessment of the morphology of bacterial cells and 
colonies, their growth requirements, as well as their fermentation profiles and other bio- 
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chemical characteristics. Culture techniques have the advantages of being relatively 
inexpensive, widely available, and suitable for physiological and biochemical studies 
(Furrie, 2006). Although culture techniques remain indispensable to conduct detailed 
metabolic and functional studies on the GI microbiota (Duncan et al., 2007), their utility 
in contemporary microbial ecology has been questioned because of their overall lack of 
representative results concerning microorganisms identifiable in a complex microbial 
ecosystem (Ritz, 2007), such as the GI tract.  
 
1.2.2 Molecular methods 
In spite of their usefulness in conducting functional studies of the GI microbiota, classic 
culture techniques are generally time consuming and labor-intensive for analysis of 
complex microbial communities (Furrie, 2006). Furthermore, culture is by definition 
restricted to cultivable organisms, and the selection of growth media can greatly affect 
results (Hartemink & Rombouts, 1999). As the large majority of bacterial species 
present in the intestinal tract are not cultivable (Pace, 1997; Eckburg et al., 2005), it is 
difficult to perform a detailed examination of the composition of the GI microbiota using 
traditional culture techniques.  
The advent of genetic-based molecular technologies by the end of the 20th 
century allowed the recognition of many novel molecular bacterial phylotypes within the 
mammalian gut (Suau et al., 1999). Most molecular methods to identify bacteria rely on 
the detection of the 16S rRNA gene, which is readily isolated and universally 
distributed, displays consistency of function, and appears to have undergone a relatively 
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slow change in base pair composition throughout evolution (Fox et al., 1980; Baker et 
al., 2003). To date, molecular techniques have been successfully employed in studies 
evaluating the microbial composition of the GI tract of cats and dogs (see below). The 
following is a brief overview over the most commonly used molecular techniques. 
 
1.2.2.1 Molecular fingerprinting  
This technique is used to separate a mixture of polymerase chain reaction (PCR) 
amplicons based on differences in base pair composition. Molecular fingerprinting 
techniques include denaturing gradient gel electrophoresis (DGGE), temperature 
gradient gel electrophoresis (TGGE), and terminal restriction fragment length 
polymorphism analysis (T-RFLP) (Muyzer, 1999; Kitts, 2001). Despite the usefulness of 
these techniques at evaluating microbial diversity quickly and reproducibly (Muyzer et 
al., 1993; Suchodolski et al., 2004), fingerprinting techniques such as DGGE or TGGE 
have a limited ability to resolve different phylotypes because the different PCR 
amplicons can have a similar melting behavior (Nikolausz et al., 2005). Also, there is a 
high frequency of additional secondary terminal restriction fragments in T-RFLP 
analysis (Egert & Friedrich, 2003), which could lead to an overestimation of microbial 
diversity. Moreover, the fingerprinting profiles may vary depending on the initial DNA 
template concentration and the type of DNA polymerase used during PCR, primer 
specificity, number of PCR cycles, as well as the annealing temperature (Jackson et al., 
2000; Osborn et al., 2000; Egert & Friedrich, 2003). 
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1.2.2.2 16S rRNA gene clone libraries and sequencing  
For identification of individual bacterial phylotypes, PCR amplicons generated using 
group-specific or universal bacterial primers can be identified using sequencing, a 
procedure which can be carried out using 16S rRNA clone libraries (Suchodolski et al., 
2008), or by automated high-throughput sequencing platforms (e.g., 454-
pyrosequencing, Illumina) (Handl et al., 2011). A 16S rRNA clone library is an 
approach to separate and identify PCR by ligating PCR amplicons into plasmid vectors, 
which are subsequently separated by transformation of vectors into E. coli. Plasmids can 
then be repurified and sequenced for identification. On the other hand, pyrosequencing, 
or sequencing by synthesis, relies on the detection of DNA polymerase activity by an 
enzymatic luminometric inorganic pyrophosphate (PPi) detection assay (ELIDA) to 
sequence DNA (Nyrén, 1987), where a successful nucleotide incorporation by the DNA 
polymerase is detected as emitted photons (Ronaghi et al. 1998). This pyrosequencing 
chemistry occurs by a DNA polymerase-driven generation of PPi, with the formation of 
ATP and ATP-dependent conversion of luciferin to oxyluciferin. This generation of 
oxyluciferin causes the emission of light pulses, and the amplitude of each signal is 
directly related to the presence of one or more nucleotides (Petrosino et al. 2009). The 
recently developed sequencer by 454 Life Sciences and Roche uses an emulsion PCR 
followed by this pyrosequencing chemistry of clonally amplified beads in a 
PicoTiterPlate (Pettersson et al. 2009). Although 454-pyrosequencing is capable to 
sequence 25 million bases in one four-hour run (Margulies et al. 2005), during last years 
Illumina and Applied Biosystems have introduced other sequencing systems with even 
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higher throughput than the 454-pyrosequencing, capable of sequencing billions of bases 
in a single run (Pettersson et al. 2009).  
 
1.2.2.3 Quantitative real-time PCR (qPCR)  
Traditional end-point PCR yields qualitative information, i.e., presence or absence of a 
given genomic target. Quantitative real-time PCR (qPCR) allows for the quantification 
of unknown genomic targets. This is made possible by including a fluorescent molecule 
in the PCR reaction that can be detected in real-time as the fluorescence increase is 
proportional to the increase in the amount of DNA generated. The fluorescent tools 
employed for this purpose include DNA-binding dyes and fluorescently labeled 
sequence-specific probes (Mackay, 2004).  
 
1.2.2.4 Fluorescent in situ hybridization (FISH) 
As mentioned before, qPCR can be utilized to quantify genomic targets (e.g., the 16S 
rRNA gene). However, the accuracy of qPCR-based quantification to enumerate 
microorganisms is limited because of the following reasons: bacteria contain different 
copy numbers of the 16S rRNA gene (Candela et al., 2004; Lee et al., 2008), there is 
preferential amplification of certain genomic targets (Sipos et al., 2007), and also fast 
growing bacterial cells have a higher amount of genomic DNA because new rounds of 
DNA replication have started before the cell has actually divided (Champness, 2007). 
Also, as mentioned before, the initial DNA template concentration and the type of DNA 
polymerase used in the PCR, primer specificity, number of PCR cycles, as well as the 
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annealing temperature, can bias the utilization of the PCR towards certain genomic 
targets. Unlike qPCR, FISH is a molecular technique that does not depend on PCR 
amplification. FISH detects nucleic acid sequences by fluorescently labeled 
oligonucleotides that hybridize to its complementary target sequence within the intact 
cell (Moter & Gobel, 2000). Limitations of FISH include the need of specialized 
equipment and training, and issues with sensitivity, as the use of this technique to detect 
low abundant microorganisms is very time-consuming and impractical.  
 
1.2.2.5 Metagenomics and transcriptomics  
As mentioned before, the detection of a single genomic target (e.g., 16S rRNA gene) 
allows for the identification and/or quantification of the GI microbiota. However, this 
approach only yields phylogenetic information (i.e., it does not provide information 
about the metabolic or functional properties of the microbiota). In contrast, new high-
throughput sequencing platforms allow for the identification of total genomic DNA or 
mRNA, thus allowing a more accurate characterization of the microbiota because there 
is no bias towards specific genes (for example, the 16S rRNA gene). These techniques 
have been recently used to study community structure as well as the functional 
properties of the canine fecal microbiota (Swanson et al., 2011).   
 
1.3 The canine GI microbiota 
Clapper & Meade (1963) attempted one of the first characterizations of bacteria and 
fungi present in the lower intestine, nose, and throat of dogs using twelve different types 
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of culture media. Using rectal swabs from 25 healthy Beagle dogs, the authors isolated 
and identified 20 species of bacteria and 10 species of fungi. Years later, Balish et al. 
(1977) isolated a total of 53 bacterial genera (187 species of microorganisms) in feces of 
male Beagle dogs housed either in an isolated germ-free environment (n=7 dogs, 129 
bacterial species) or in an open environment (n=2 dogs, 58 bacterial species). These 
results were among the first to suggest a potential environmental effect (i.e., housing 
conditions) on canine fecal microbial diversity. Using the same dogs, Davis et al. (1977) 
showed that the quantitative and qualitative distribution of bacteria varies along the 
different segments of the canine GI tract. The authors confirmed the effect of housing 
conditions on the canine GI microbiota by showing several qualitative and quantitative 
changes along the GI microbiota between the two groups of dogs (i.e., isolated and open 
environment). Also, the authors showed that the ileum of dogs possesses heterogeneous 
populations of bacteria, and that their abundance in this intestinal region is more variable 
than in the cecum or the colon. Also, using culture techniques, Devriese et al. (1992) 
reported that Enterococcus faecalis was the most frequently isolated Enterococcus spp. 
from anal swabs of healthy dogs (n=60), whereas Streptococcus canis and S. bovis were 
the most frequently isolated Streptococcus spp. Notably, the culture techniques utilized 
in this study could not identify 16% of all the isolates (47/288) as either Enterococcus or 
Streptococcus spp., suggesting a limitation of culture methods in identifying bacterial 
groups in the canine GI tract. Also, using culture techniques, Mentula et al. (2005) 
showed that the aerobic/facultative anaerobic and anaerobic bacteria were equally 
represented in the jejunum of Beagle dogs (n=22), whereas anaerobes predominated in 
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feces. Despite lower numbers of total bacterial organisms in the jejunum (102-106 cfu/g 
wet weight of intestinal fluid) than in feces (108-1011 cfu/g feces), Staphylococcus spp. 
and non-fermentative gram-negative rods were more prevalent in the small intestine. 
Similarly to the observations made by Davis et al. (1977), the authors also showed that 
the small intestine of dogs contains only few bacterial species at a time with vastly 
fluctuating counts, whereas the results obtained from the colon showed that the major 
bacterial groups remain relatively constant over time (Mentula et al., 2005). Also, using 
traditional culture methods, Buddington et al. (2003) showed that the entire GI tract of 
Beagle dogs (n=110) was colonized by day 1 after birth, and that postnatal development 
was associated with changes in the relative proportions of the various groups of bacteria 
with anaerobic groups increasing in absolute and relative numbers. 
The recent use of molecular technologies revealed that traditional culture 
techniques were underestimating the composition of the GI microbiota (Vaughan et al., 
2000).  Greetham et al. (2002) were among the first in using both a culture and a 
genotyping approach to describe the composition of the canine GI microbiota. By 
sequencing the 16S rRNA gene from cultured isolates, they were able to identify 157 out 
of 171 bacterial colonies (14 colonies were not recovered due to technical difficulties) 
from the feces of one Labrador retriever. However, the gene sequences of many of the 
isolates (29% of total) did not correlate with known sequence information deposited in 
the Ribosomal Database Project at the time, suggesting the presence of novel bacterial 
phylotypes in the canine GI tract. The authors concluded that traditional culture methods 
failed to reflect the bacterial diversity in feces of Labrador retrievers. Years later, 
 9
Suchodolski et al. (2004) applied a fingerprinting technique (DGGE) to study the 
intestinal bacterial diversity in dogs (n=14). In this study, the obtained banding profiles 
suggested that dogs harbored a highly individualized and previously uncharacterized 
bacterial profile in the duodenum. A year later, the same research group expanded these 
results and showed that dogs had a higher bacterial diversity in the large intestine (i.e., 
colon and rectum) when compared with all sections of the small intestine (i.e., 
duodenum, jejunum, and ileum) (Suchodolski et al. 2005). More recently, Jia et al. 
(2010) investigated the abundance of selected groups of the fecal microbiota of healthy 
dogs (n=8) and dogs with chronic diarrhea (n=9) using fluorescence in situ 
hybridization, and showed that the Atopobium cluster (mainly the genera Atopobium and 
Coriobacterium), Lactobacillus-Enterococcus group, and Clostridium cluster XIVa were 
major fecal bacterial groups in dogs. More recently, Middelbos et al. (2010) for the first 
time used a new generation 454-pyrosequencing to describe the composition of the fecal 
microbiota in dogs (n=6), and showed that Fusobacteria (23-40%), Firmicutes (14-28%), 
and Bacteroidetes (31-34%) were the co-dominant fecal bacterial phyla. These results 
were similar to the results of another recent 454-pyrosequencing approach to evaluate 
the canine fecal microbiota where Firmicutes, Bacteroidetes, Proteobacteria, and 
Actinobacteria made up >99% of total bacteria (Handl et al., 2011). However, 
Firmicutes was by far the most abundant phylum (>90%). This would suggest that 
differences in DNA extraction procedures and/or primer selection may yield different 
abundance results between studies. Finally, a recent study used a phylogenetic and gene-
centric metagenomics approach (i.e., analysis of a community from the viewpoint of its 
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component genes rather than its component organisms) to study the intestinal 
microbiome of dogs (n=6) and revealed similarities between canine, human, and mouse 
intestinal metagenomes (Swanson, et al., 2011).  
 
1.4 The feline GI microbiota 
Osbaldiston & Stowe (1971) were among the first to investigate the intestinal microbiota 
of cats. The authors isolated a variety of microorganisms in the colon of healthy cats 
(n=12), including Enterococcus, Streptococcus, Staphylococcus, Escherichia, 
Clostridium, and Lactobacillus spp. Another early study compared the fecal microbiota 
of conventional cats and specific pathogen free cats using culture techniques (Itoh et al., 
1984). Sparkes et al. (1998) detected a total of 66 bacterial groups (species or genera, 43 
aerobes and 23 anaerobes) in the duodenum of healthy cats (n=12). In addition to this 
higher qualitative abundance of aerobes in the feline duodenum, the authors showed that 
the numbers of aerobic bacteria were also higher than the numbers of anaerobic bacteria. 
Also in this study, only five bacterial groups (Enterococcus faecalis, Clostridium 
perfringens, Bacteroides, Pasteurella, and Streptococcus spp.) were present in more than 
50% of all intestinal aspirates. Similarly, Johnston et al. (1999) isolated a mixture of 
aerobic, anaerobic, and microaerophilic bacteria, including Bacillus, Bacteroides, 
Clostridium, Corynebacterium, Lactobacillus, Neisseria, and Streptococcus spp. from 
the duodenal aspirates of healthy cats (n=7).  
Using fluorescent in situ hybridization, Inness et al. (2007) evaluated the 
composition of the fecal microbiota in cats and showed that the feces of healthy animals 
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(n=34) contained an average of 10.3x1010 bacterial cells per gram of feces, whereas cats 
with inflammatory bowel disease (n=11) had a slightly lower average of 10.0x1010. As in 
dogs, recent studies using cloning and sequencing of the 16S rRNA gene have shown a 
higher bacterial diversity in the large intestine of healthy cats when compared with the 
small intestine (Ritchie et al., 2008). Desai et al. (2009) sequenced the gene encoding 
the universal 60 kDa chaperonin (cpn60) and showed that the fecal microbiota of cats 
(n=9) was dominated by Actinobacteria (particularly Bifidobacterium) and Firmicutes 
(particularly Lactobacillus). The authors confirmed these results using quantitative real-
time PCR and showed that, although there was substantial animal-to-animal variation, 
most targets were detected in all cats. Finally, Ritchie et al. (2010) studied the diversity 
of the fecal microbiota of healthy cats (n=15) using universal 16S rRNA gene primers 
and showed that the majority of the sequences were assigned to the phylum Firmicutes 
(87.3%), followed by Proteobacteria (7.9%), Bacteroidetes (2.4%), Actinobacteria 
(2.3%), and Fusobacteria (0.2%). These proportions of bacterial phyla are somewhat in 
agreement with a more recent evaluation of the feline fecal microbiota using 454-
pyrosequencing (Handl et al., 2011), which also showed a high proportion (~90%) of 
Firmicutes and a low proportion (< 10%) of all other phyla in fecal samples of healthy 
cats. 
 
1.5 Host health and the GI microbiota  
The GI microbiota is intimately related to gastrointestinal and overall health of the host. 
One of the main physiological phenomena linking host health and the GI microbiota is 
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microbial fermentation in the large intestine, where anaerobic bacteria break down 
undigested carbohydrates to short chain fatty acids (SCFA), which are rapidly absorbed 
by the colonic epithelium (Herschel et al., 1981; Wong et al., 2006). This symbiosis 
enables the host to salvage nutrients that would otherwise be lost by excretion from the 
digestive tract. In cats, one study showed that concentrations of volatile fatty acids were 
greatest in the proximal and distal portion of the colon when compared to the upper GI 
tract (Brosey et al., 2000), suggesting the presence of a different microbiota in the 
different segments of the GI tract. SCFA have long been known to affect colonic 
epithelial cell transport, metabolism, growth, and differentiation of colonocytes, and 
hepatic metabolism of lipids and carbohydrates. They also provide energy to muscle, 
kidney, heart, and brain (Cummings & Macfarlane, 1997; Cook & Sellin, 1998; McOrist 
et al., 2008). The GI microbiota is also known to stimulate the development of the 
immune system in young animals (Bauer et al., 2006). Furthermore, intestinal bacteria 
can degrade free amino acids and small peptides, thus contributing to the recycling of 
nitrogen (Metges, 2000; Bergen & Wu, 2009). Moreover, certain bacterial populations in 
the GI tract are known to produce metabolic substrates for the host, such as E. coli and 
various Bacteroides spp. who produce menaquinones (Vitamin K2) (Ramotar et al., 
1984), and Enterococcus spp. that are capable of synthesizing folate (Camilo et al., 
1996). Colonic bacteria such as Lactobacillus and Bifidobacterium spp. may also 
contribute to the salvage of bile acids that escape active transport in the distal ileum 
(Ridlon et al., 2006). Yet other intestinal bacteria, such as Enterococcus casseliflavus 
and Eubacterium ramulus may aid in the bio-transformation of polyphenols (Schneider 
 13
et al., 1999), a group of compounds that may confer a health benefit to the host due to 
their high antioxidant activities (Lambert et al., 2007). Finally, SCFA produced during 
fermentation have been shown to stimulate motility of the feline colon (Rondeau et al., 
2003) and the canine ileum in a concentration-dependent manner (Kamath et al., 1987), 
suggesting a role of colonic bacteria in the overall digestive process of the GI tract.  
 
1.6 The GI microbiota in disease 
Batt and McLean (1987) performed one of the first studies to explore the relationship 
between the composition of the intestinal microbiota and intestinal mucosal damage in 
dogs with either aerobic or anaerobic bacterial overgrowth in the jejunum. Traditionally, 
small intestinal bacterial overgrowth (SIBO) was defined as a clinical syndrome 
characterized by an abnormal accumulation of bacteria in the small intestine (Johnston, 
1999). However, this definition has changed over the years. SIBO has also been known 
synonymously as antibiotic-responsive diarrhea (German et al., 2003) or tylosin-
responsive diarrhea (Westermarck et al., 2005). Today, there is little doubt that the 
intestinal microbiota plays an important role in GI disease (Cave, 2003; Marks & Kather, 
2003; Stecher & Hardt, 2008), but the nature of the relationship is still elusive. For 
example, one study showed that only a combination of methods (ELISA and culture) can 
provide credible evidence for the presence of enterotoxigenic C. perfringens in the feces 
of dogs with diarrhea (Marks et al., 2002). Also, while some authors believed that 
bacterial culture of duodenal juice remains necessary for definite diagnosis of SIBO 
(Rutgers et al., 1995), it has been shown that SIBO, as assessed by quantitative culture, 
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is associated with mucosal damage not detected on histological examination of intestinal 
biopsies (Rutgers et al., 1996), and one study did not find strong evidence of a 
relationship between duodenal bacterial numbers and a clinical response to antibiotics, 
questioning the utility of quantitative duodenal juice culture for the diagnosis of SIBO in 
canine patients with gastrointestinal signs (German, et al., 2003). Despite this 
controversy regarding the relationship between intestinal bacteria and clinical disease, a 
higher prevalence of enteropathogenic E. coli was observed in feces of dogs with acute 
(n=57) and chronic (n=82) diarrhea when compared to healthy controls (n=122) (Sancak 
et al., 2004). Also, a strain of E. coli, with similar phenotypic behavior of the Crohn’s 
disease-associated strain E. coli LF 82, has been linked to granulomatous colitis in Boxer 
dogs with this disease (n=13) when compared to healthy controls (n=38) (Simpson et al., 
2006). Moreover, one study showed that total bacteria, Bifidobacterium, and Bacteroides 
counts in feces were all significantly higher in healthy cats (n=34) when compared to 
cats with IBD (n=11), whereas Desulfovibrio spp. (producers of toxic sulphides) 
numbers were significantly higher in the cats with IBD (Inness, et al., 2007). Also, 
diarrheic episodes have been associated with increased fecal levels of C. perfringens, 
Enterococcus faecalis, and Enterococcus faecium in dogs (n=12) (Bell et al., 2008). In 
addition, changes in microbiota composition have been associated with alteration of the 
host immune response. For example, the expression of several Toll-like receptors 
(TLRs), which are capable of recognizing microbe-associated molecular patters, has 
been shown to be upregulated in dogs with IBD (Burgener et al., 2008; McMahon et al., 
2010). Similarly, one study showed that the expression of some of these TLRs was 
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increased in all intestinal segments (i.e., duodenum, colon, and ileum) in German 
Shepherd dogs with chronic enteropathies (Allenspach et al., 2010).  
The relationship between the GI microbiota and GI disease may involve specific 
groups of microorganisms (e.g., E. coli, C. perfringens) or groups of microorganisms. 
One study evaluated the relationship of duodenal mucosal bacteria to intestinal 
inflammation and clinical disease in cats with IBD, showing that the number of mucosa-
associated Enterobacteriaceae was higher in cats with signs of GI disease (n=17) than in 
healthy control cats (n=10) (Janeczko et al., 2008). Also, one study showed that dogs 
with IBD (n=7) had a higher abundance of all three main bacterial classes within the 
phylum Proteobacteria in the duodenum, when compared with healthy dogs (n=7) 
(Suchodolski et al., 2010). In addition to bacteria, there could also be an involvement of 
fungal organisms in chronic intestinal enteropathies (Suchodolski et al., 2008), but more 
research is needed to study these organisms (Handl, et al., 2011). 
 
1.7 Factors influencing the GI microbiota 
The composition and function of the GI microbiota is affected by numerous factors 
associated with both the host and the surrounding environment. Early studies by Balish 
et al. and Davis et al. in the 1970’s were among the first to suggest that different housing 
conditions could be associated with differences in the GI microbiota of dogs. Also, one 
study examined the GI microbiota of two age groups of dogs and showed that in all 
regions of the large intestine (i.e., cecum, colon, and rectum), the levels of Bacteroides, 
Eubacterium, Peptostreptococcus, Bifidobacterium, Lactobacillus, and Staphylococcus 
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spp. in the elderly dogs (n=8, older than 11 years of age) were lower than those in 
younger animals (n=8, younger than one year of age) (Benno et al., 1992). Similarly, 
Simpson et al. (2002) studied the effect of age, breed, and diet on fecal bacterial 
populations of dogs (n=18). In this study, selected aerobic and anaerobic plate counts 
showed significant effects of breed and age, while no significant effect of diet was 
found. High dietary protein concentrations may also lower the fecal abundance of E. 
coli, Bifidobacterium and Lactobacillus spp. in young cats (n=17) (Vester et al., 2009). 
In addition, the authors of this study showed that the numbers of C. perfringens and 
Streptococcus spp. were higher in elderly animals when compared to younger dogs. 
Moreover, Zentek et al. (2003) reported an increase in fecal culture counts of 
Clostridium perfringens in Beagle dogs (n=6) fed a high protein diet (66.3%), but other 
bacterial groups, such as Streptococcus and Lactobacillus spp. were not significantly 
affected. In this study, fecal ammonia concentrations also increased significantly with 
the high protein diet. Similarly, a high protein diet (52.9% protein in the diet) has also 
been shown to increase counts of C. perfringens in feces of healthy cats (n=8) (Lubbs et 
al., 2009), as assessed by quantitative real-time PCR. In this study there was also a 
decrease in Bifidobacterium spp. during consumption of the high protein diet, but 
Lactobacillus and E. coli were not significantly affected by the treatment and fecal 
ammonia concentrations were not investigated.  
Prebiotics and/or probiotic microorganisms are also known to modify the 
composition and function of the GI microbiota of cats and dogs. Sunvold et al. (1995) 
investigated the in vitro effect of dietary fiber on the metabolic behavior of the fecal 
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microbiota. The authors showed in dogs that a non-fermentable fiber (8.0% in the diet) 
yielded a lower in vitro organic matter disappearance and a higher acetate-to-propionate 
ratio when compared with a fermentable fiber (14.5% in diet) (Sunvold et al., 1995). 
Similarly, the authors also showed that in cats a diet containing no supplemental fiber 
yielded a greater acetate-to-propionate ratio when compared with a diet containing beet 
pulp (12.5% in diet). Later, Sparkes et al. (1998) studied the effect of ingested 
fructooligosaccharides (0.75% in diet) on duodenal bacteria of healthy cats (n=12), but 
did not observe significant changes in aerobic, anaerobic, or total bacteria, as assessed 
by culture methods. Similarly, Willard et al., also using culture methods (2000), did not 
observe changes in fecal concentrations of Clostridium spp. or E. coli after the addition 
of 1.0% FOS to the diet of healthy dogs (n=6). Marshall-Jones et al. (2006) evaluated 
the effect of orally administered Lactobacillus acidophilus (strain DSM13241, 108 
cfu/day) on the fecal microbiota of healthy cats (n=15) for a period of 4.5 weeks. Culture 
techniques revealed that the fecal concentrations of Lactobacillus spp. were not 
increased during administration of the probiotic, but the treatment was associated with 
lower counts of Clostridium spp., total coliforms, and Enterococcus spp. In contrast to 
the results obtained with culture methods, fecal Lactobacillus spp. were significantly 
increased during probiotic administration in both absolute numbers and as a percentage 
of the total bacterial population as assessed by FISH. In contrast, using FISH, 
Bifidobacterium spp. and Enterococcus faecalis were decreased during administration of 
the probiotic (Marshall-Jones, et al., 2006). One study showed that low-level fructan 
supplementation enhances digestion in dogs (n=5), but does not alter fecal microbial 
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populations (Barry et al., 2009). Another study showed that dietary cellulose, 
fructooligosaccharides, and pectin modify protein catabolites and microbial populations 
in the feces of adult cats (n=12) (Barry et al., 2010). In addition to the level of protein in 
the diet, probiotics and prebiotics, other environmental factors such as antibiotics 
(Suchodolski et al., 2009; Gronvold et al., 2010), and therapeutic drugs such as proton 
pump inhibitors (Lombardo et al., 2010) have been shown to lead to alterations in the 
abundance of intestinal bacterial groups. Overall, these studies show that fluctuations in 
the GI microbiota of cats and dogs in response to environmental factors can be analyzed 
using culture-independent molecular techniques. Finally, as discussed before, disease 
episodes can lead to changes in the GI microbiota. Xenoulis et al. (2008) used 16S 
rRNA gene clone libraries and reported that the duodenum of dogs with IBD (n=10) may 
be composed of distinct microbial communities when compared with healthy dogs 
(n=9), especially within the members of the family Enterobacteriaceae. 
 
1.8 Hypotheses and research objectives 
The hypotheses of this study are that: 1) a multi-species synbiotic formulation will 
change the composition of the fecal microbiota in healthy cats and dogs; 2) age, baseline 
bacterial populations, and body weight will serve as significant predictors of intestinal 
colonization by ingested probiotic bacteria in healthy cats and dogs; and 3) the proton-
pump inhibitor omeprazole will change the composition of the gastric, duodenal, and 
fecal microbiota in healthy dogs.  
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The objectives of the proposed research project were 1) to evaluate the effect of a 
multi-species synbiotic formulation on fecal bacteria of healthy cats and dogs, 2) to 
investigate the effect of age, baseline bacterial populations, and body weight as 
predictors of intestinal colonization by ingested probiotic bacteria in healthy cats and 
dogs, 3) to evaluate the effect of the proton-pump inhibitor omeprazole on gastric, 
duodenal, and fecal bacterial populations of healthy dogs, and 4) to characterize the 
abundance of predominant bacterial groups in feces of healthy dogs using fluorescence 
in situ hybridization.  
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2. EFFECT OF A MULTI-SPECIES SYNBIOTIC ON FECAL MICROBIOTA OF 
HEALTHY CATS AND DOGS 
 
2.1  Overview 
The effect of a multi-species synbiotic on the fecal microbiota of healthy cats (n=12) and 
dogs (n=12) was evaluated. The synbiotic (containing 5x109 colony-forming units of a 
mixture of seven probiotic strains, and a blend of fructooligosaccharides and 
arabinogalactans) was administered daily for 21 days. Fecal and serum samples were 
collected before, during, and up to three weeks after administration. Changes in the fecal 
microbiota were analyzed using denaturing gradient gel electrophoresis, 16S rRNA gene 
libraries, quantitative real-time PCR, and 16S rRNA gene 454-pyrosequencing. Probiotic 
species were detectable in 10/12 dogs and 11/12 cats during product administration. 
Abundances of Enterococcus and Streptococcus spp. were significantly increased in at 
least one time point during administration, and returned to baseline abundance after 
treatment was discontinued. No changes in the major bacterial phyla were identified on 
454-pyrosequencing. No adverse gastrointestinal effects were recorded and no 
significant changes in gastrointestinal function or immune markers were observed during 
the study period. This study shows that while the ingestion of probiotics and prebiotics 
does not appear to alter the predominant bacterial phyla present in feces, 
supplementation with the investigated synbiotic leads to an increased abundance of 
probiotic bacteria in the feces of healthy cats and dogs. 
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2.2 Introduction 
Probiotics are live microorganisms, which when consumed in adequate amounts confer a 
health benefit on the host (FAO/WHO, 2002). Prebiotics are defined as selectively 
fermented ingredients that result in changes in the composition and/or activity of the 
gastrointestinal microbiota, thus also conferring health benefits on the host (Gibson et 
al., 2010), and synbiotics are preparations containing both probiotics and prebiotics. 
Formulations containing probiotics and/or prebiotics are increasingly used in human and 
veterinary medicine, as they could potentially be useful to treat and/or prevent 
gastrointestinal as well as extra-gastrointestinal disorders (Roberfroid et al., 2010; 
Wolvers et al., 2010).  
Probiotics can enhance intestinal health by several mechanisms, including 
displacement of intestinal pathogens (Lee et al., 2003), production of antimicrobial 
substances (Jones & Versalovic, 2009), and/or enhancement of immune responses 
(Pagnini et al., 2010). The success of these mechanisms in promoting health is thought 
to be dependent on an increased abundance of probiotic organisms in the intestinal tract 
(Kailasapathy & Chin, 2000). This hypothesis has led to numerous investigations 
addressing the survival (Bezkorovainy, 2001; Elli et al., 2006) and colonization (Valeur 
et al., 2004; Pagnini et al., 2010) properties of probiotics after oral ingestion as 
enhancers of health.  
The increased abundance of probiotics in the intestinal tract after oral ingestion 
has traditionally been thought to modify the composition of the intestinal microbiota 
(Fuller, 1989). However, to date most investigations have only studied the effect of 
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probiotics on select intestinal bacterial groups (Sauter et al., 2006; Biagi et al., 2007; 
Saulnier et al., 2008), in part due to the challenges associated with the characterization 
of highly complex microbial ecosystems. Recently developed cost-effective high 
throughput technologies (e.g., microarray based methods or massive parallel 
pyrosequencing techniques) allow a deeper phylogenetic coverage of the intestinal 
microbiota (Zoetendal et al., 2008; Suchodolski et al., 2009; Middelbos et al., 2010; 
Swanson et al., 2011; Handl et al., 2011) and, therefore, may be useful to assess the 
effect of probiotics and/or prebiotics on the overall composition of the intestinal 
microbiota (Middelbos et al., 2010). 
The effect of probiotics on intestinal and overall health has been studied in 
humans (Culligan et al., 2009), but much more limited data are available for veterinary 
species (Callaway et al., 2008). While probiotics and prebiotics are administered to dogs 
and cats with increasing frequency, only few investigations have evaluated the effect of 
these preparations on intestinal microbial composition and immune function of these 
animal species (Baillon et al., 2004; Marshall-Jones et al., 2006; Kelley et al., 2009; 
Ogue-Bon et al., 2010). Because extrapolations of the in vivo effect of probiotics among 
animal species are inherently weak, the effect of probiotic preparations on the intestinal 
microbiota of the target animal population deserves investigation. The objective of this 
study was to evaluate the effect of a multi-species synbiotic preparation designed for use 
in cats and dogs on the fecal bacterial microbiota of these animal species. Changes in 
fecal bacterial groups were evaluated using denaturing gradient gel electrophoresis 
(DGGE), comparative 16S rRNA gene analysis, quantitative real-time PCR (qPCR) 
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assays, as well as massive parallel 16S rRNA gene 454-pyrosequencing. Selected 
markers of gastrointestinal and immune function were also evaluated to investigate 
potentially beneficial effects due to the consumption of the synbiotic.  
 
2.3 Materials and methods 
2.3.1 Synbiotic description  
Proviable®-DC (Nutramax Laboratories, Inc. Edgewood, MD) is a commercially 
available multi-species synbiotic formulation designed for use in cats and dogs that 
contains a blend of fructooligosaccharides (FOS), arabinogalactans, and a total of five 
billion (5x109) colony-forming units of a mixture of seven bacterial species per capsule 
(Table 1). The exact proportions of each component in the formulation (bacterial strains 
and prebiotics) are proprietary. 
 
2.3.2 Animal subjects and study design  
Privately owned healthy cats (n=12) and dogs (n=12) of different breeds and ages were 
enrolled (Table 2). None of the enrolled subjects had a history of antibiotic use or any 
other medication known to influence the intestinal microbiota for at least three months 
before the beginning of the study. All animal subjects were fed different commercial 
diets. 
 Baseline blood and fecal samples were collected before synbiotic administration 
(day 0). All cats and dogs then received one capsule of the formulation daily for 21 days. 
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Table 1. Probiotic bacterial strains in Proviable®-DC 
Bacterium Strain 
Enterococcus faecium NCIMB 30183 
Streptococcus salivarus subsp. thermophilus NCIMB 30189 
Bifidobacterium longum NCIMB 30179 
Lactobacillus acidophilus NCIMB 30184 
Lactobacillus casei subsp. rhamnosus NCIMB 30188 
Lactobacillus plantarum NCIMB 30187 
Lactobacillus delbrueckii subsp. bulgaricus NCIMB 30186 
 
 
 
Owners were allowed to administer the capsule orally, mix the capsule into food, or 
open the capsule and mix the preparation contained in the capsule into the food, 
depending on the particular way of their pets to accept medications (Table 2). Owners 
(mainly students of Veterinary Medicine at Texas A&M University) were instructed to 
maintain the usual diet and asked to complete a daily questionnaire during the 21 days of 
synbiotic administration to record clinical signs of gastrointestinal discomfort such as 
diarrhea, vomiting, and/or abdominal pain. Additional serum samples were obtained on 
day 21 (last day of synbiotic administration) and day 42 (three weeks after cessation of 
administration of the synbiotic). Additional fecal samples were collected every 3 to 4 
days during and up to three weeks after administration of the synbiotic. All subjects were 
maintained on their typical diet during the study period. The study protocol was 
approved by the Clinical Research Review Committee of Texas A&M University and 
written informed consent was obtained from the owners of all enrolled animals. 
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2.3.3 Assessment of fecal microbiota  
Extraction of DNA. An aliquot of 100 mg (wet weight) of each fecal sample was mixed 
with 500 μL of lysis buffer (Purege® cell lysis solution, Gentra Systems, Minneapolis, 
MN) and 100 μL of 0.1 mm-diameter zirconia beads (BioSpec Products Inc., 
Bartlesville, OK). This mixture was vortexed for 5 min at maximum speed on a standard 
vortex. After centrifugation (7 min at 12,000 g), the supernatant was transferred into a 
Table 2. Summary statistics for the enrolled cats and dogs. Information about the 
breed, age, weight, body condition score (BCS), type of food consumed, and the 
mode of administration of the synbiotic formulation are provided. Probiotic species 
were detected during the administration period either using universal bacterial 
primers (DGGE) or genus-specific primers (16S rRNA gene clone libraries) for 
Bifidobacterium and Lactobacillus spp 
Cat Breed Age 
(years) 
Weight 
(pounds) 
BCS Food Administration of 
probiotic 
DGGE Clone 
libraries 
1 DSH 5.0 13 7 dry powder in food yes N/A 
2 Mixed 0.7 9.5 5 dry capsule in food yes yes 
3 DSH 2.5 12 6 dry capsule by mouth yes no 
4 DSH 6.7 11 nn dry powder in food yes yes 
5 DSH 1.3 12.7 5 dry capsule by mouth yes yes 
6 DLH 1.7 9.2 4 dry powder in food yes no 
7 DSH 1.4 9.3 5 dry powder in food no no 
8 Persian 1.2 8.3 4 raw powder in food yes yes 
9 DSH 4.8 11.5 5 dry powder in food yes yes 
10 DMH 2.8 11.1 5 dry powder in food yes yes 
11 DSH 4.2 11 6 dry powder in food yes yes 
12 DSH 3.0 10.8 6 dry/can powder in food yes yes 
       92% 73% 
Dog         
1 Mixed 10.2 63 6 dry capsule by mouth yes no 
2 Mixed 0.8 10.2 4 dry capsule by mouth no yes 
3 Blue Heeler 3.7 59.5 8 dry capsule by mouth yes yes 
4 Lab Retriever 1.9 55.5 5 dry capsule by mouth no yes 
5 Min Dachshund 3.5 11.5 5 dry capsule by mouth N/A N/A 
6 Mixed 2.8 69 4 dry capsule by mouth no yes 
7 Mixed 3.7 10 6 dry capsule in food no no 
8 Corgi 0.9 24.8 5 dry powder in food no yes 
9 Mixed 0.7 35 4 dry capsule by mouth no yes 
10 Boxer 5.0 75 7 dry powder in food yes yes 
11 Chesapeake 7.9 64 5 dry capsule by mouth yes yes 
12 Lab Retriever 6.9 81.5 5 dry capsule by mouth yes yes 
       45% 82% 
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sterile tube and mixed with 500 μL of a solution of phenol-chloroform-isoamyl alcohol 
(Applied Biosystems, Foster City, CA). Further steps of DNA extraction and purification 
were performed as previously described (Suchodolski et al., 2005).  
 Denaturing Gel Gradient Electrophoresis (DGGE). To first investigate whether 
the synbiotic led to a noticeable change on the fecal microbiota, qualitative changes in 
fecal bacterial communities were evaluated by DGGE at baseline, day 21 (last day of 
synbiotic administration) and day 38 (two weeks after treatment) with some 
modifications to a protocol described previously (Suchodolski et al., 2004). Briefly, 
universal bacterial primers F341 and R518 (Table 3) were used to amplify the variable 
V3 region of the 16S rRNA gene. A GC clamp 
(CGCCCGGGGCGCGCCCCGGGCGGGGCGGGGGCACGGGG) was incorporated 
into the forward primer to prevent the complete dissociation of the DNA double strand 
during the subsequent DGGE analysis. PCR amplicons were loaded on 8% (w/v) 
polyacrylamide gels in TAE buffer with a linear denaturing gradient of 40% to 60%. 
Electrophoresis was performed in TAE buffer at 60 °C for 16 h at 70 V. Gels were 
stained with ethidium bromide for 12 min, destained in water two times for 30 min and 
visualized under UV light.   
 16S rRNA gene clone libraries. In addition to a change in the qualitative 
composition of the fecal microbiota, it was also of interest to investigate in feces the 
presence of closely related probiotic genera (see qPCR below) and species over time. 
Changes in fecal Bifidobacterium and Lactobacillus spp. were assessed using 16S rRNA 
gene clone libraries at baseline, during the last week of synbiotic administration (days 
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14-17), and two weeks after discontinuation of treatment (days 32-38). Genus-specific 
primers (Table 3) were used to amplify a 308 and 480 bp amplicon of the 16S rRNA 
gene of Lactobacillus and Bifidobacterium spp., respectively, as described previously 
(Ritchie et al., 2010; Handl et al., 2011).  
 
 
 
Table 3 Oligonucleotides used for the amplification of bacterial targets 
 
Target 
 
Sequence (5’-3’) 
Annealing 
Temperature 
(°C)  
 
Reference 
Bifidobacterium spp. F- TCGCGTCCGGTGTGAAAG 60 Rinttila et al. (2004) 
 R- CCACATCCAGCATCCAC   
Enterococcus spp. F- CCCTTATTGTTAGTTGCCATCATT 61 Malinen et al. (2005) 
 R- ACTCGTTGTACTTCCCATTGT   
Lactobacillus spp. F- AGCAGTAGGGAATCTTCCA 58 Malinen et al., (2005) 
 R- CACCGCTACACATGGAG   
Streptococcus spp. F- TTATTTGAAAGGGGCAATTGCT 54 Furet et al. (2004) 
 R- GTGAACTTTCCACTCTCACAC   
All bacteria F- CCTACGGGAGGCAGCAG 57 Muyzer et al. (1993) 
 R- ATTACCGCGGCTGCTGG   
 
 
 
Quantitative real-time PCR (qPCR). Quantitative changes in the fecal abundance of 
probiotic groups were assessed by qPCR before, during (days 1, 8, and 17 in cats and 
days 3, 5, and 17 in dogs) and after (days 26, 29, and 38 in cats and days 23, 26, and 38) 
synbiotic administration, depending on the availability of fecal DNA samples. Bacterial 
DNA was amplified using bacterial universal and 16S rRNA gene genus-specific 
primers (Table 3) for all four probiotic genera (Enterococcus, Lactobacillus, 
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Bifidobacterium, and Streptococcus spp.) using SYBR Green-based assays (Biorad 
Laboratories, Hercules, CA, USA). Standard curves using 1:10 dilutions of DNA 
(ranging from 2 ng to 0.2 pg) from lyophilized bacterial species of each genus and 
canine fecal DNA for universal bacteria were used to calculate the unknown bacterial 
genomic targets. All samples and standards were run in duplicate. A commercial real-
time PCR thermocycler (iCycler iQ, Biorad) was used for all experiments with the 
following PCR protocols: 95 °C for 3 min for enzyme activation, 35 cycles consisting of 
10 s at 95 °C, 15 s at optimized annealing temperature (Table 3) and extension for 10 s at 
72 °C. The PCR mixture (25 µL) contained 12.5 µL of iQTM SYBR® Green Supermix 
(Biorad), 9.7 μL of sterile water, 0.4 μL of each primer (final concentration: 160 nmol) 
and 2 μL of DNA (~ 5 ng μL-1). After all PCR cycles were completed, a melt-curve 
analysis was performed for all assays under the following conditions: 1 min denaturation 
at 95 °C, 1 min annealing at 55 °C, and 80 cycles of 0.5 °C increments (10 s each) 
beginning at 55 °C. The log10 16S rRNA gene copies from each bacterial genera was 
normalized to the log10 16S rRNA gene copies of all bacteria (log10 16S rRNA gene 
copies from each bacterial group divided by the log10 16S rRNA gene copies of all 
bacteria) for statistical comparisons (Frank et al., 2007). 
 Massive parallel 16S rRNA gene pyrosequencing. Fecal bacterial communities 
were evaluated using pyrosequencing at baseline (day 0), after five days of feeding the 
synbiotic (day 5) and after two days of discontinuation of synbiotic administration (day 
23) using a bacterial tag-encoded FLX-titanium 16S rRNA gene amplicon 
pyrosequencing (bTEFAP) as described previously for canine and feline fecal samples 
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(Handl et al., 2011). Sequences with identity scores greater than 97% identity (< 3% 
divergence) were resolved at the species level, between 95% and 97% at the genus level, 
between 90% and 95% at the family level, and between 80% and 90% at the order level. 
To assess the diversity of the fecal microbiota, the Shannon-Weaver diversity index was 
calculated. High values for this diversity index indicate higher bacterial diversity. To 
investigate potential clustering of the microbial communities before, during, and after 
administering the synbiotic, principal component analysis (PCA) based on the 
phylogeny-based Unifrac method (Lozupone & Knight, 2005) was applied using the data 
generated by pyrosequencing. 
 
2.3.4. Parameters of GI and immune function  
Parameters in serum. All serum assays were measured before synbiotic administration 
(day 0), on day 21 (last day of synbiotic administration), and 42 (three weeks after end 
of treatment). A complete blood count and serum chemistry profile were analyzed at the 
Texas Veterinary Medical Diagnostic Laboratory (College Station, TX). Serum 
concentrations of IgA were measured using a commercial ELISA assay (Bethyl 
Laboratories, Montgomery, TX). Serum concentrations of cobalamin (competitive 
immunoassay, Immulite 2000 Vitamin B12®, Siemens, Los Angeles, CA), folate 
(competitive immunoassay, Immulite 2000 Folic acid®, Siemens), trypsin-like 
immunoreactivity (TLI, for dogs a radioimmunoassay (RIA) from Siemens, for cats an 
in-house RIA), and pancreatic lipase immunoreactivity (PLI, for dogs Spec cPL® from 
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Idexx Laboratories Westbrook, ME, for cats an in-house RIA) were analyzed at the 
Gastrointestinal Laboratory (College Station, TX).  
 Parameters in feces. Fecal IgA concentrations were measured in canine feces 
before (day 0), during (day 21, last day of synbiotic administration), and after (day 42) 
synbiotic administration using an ELISA that has been validated for measurement of IgA 
concentrations in canine feces (Tress et al., 2006). The analysis of fecal IgA in cats was 
not performed because to date there is no validated assay available. Canine and feline 
fecal α1-proteinase inhibitor (α1-PI) concentrations were measured at day 0, day 21, and 
day 42 using species specific in-house immunoassays (Melgarejo et al., 1998; Fetz et al., 
2004), respectively. 
 
2.3.5 Statistical analysis 
A repeated measures analysis of variance (ANOVA) or its non-parametric counterpart, 
Friedman’s test, was used to compare the following dependent variables: the results of 
gastrointestinal and immune function tests, serum chemistry, complete blood counts, 
changes in microbial composition based on 16S rRNA gene pyrosequencing, bacterial 
abundance based on qPCRs, and Shannon-Weaver diversity indices, across different 
levels of the independent variable time (before, during and after synbiotic 
administration) using Prism5 (GraphPad Software Inc., San Diego, CA). The assumption 
of normality was tested using the D’Agostino and Pearson normality test (GraphPad 
Software Inc.). For all tests, a P<0.05 was considered statistically significant to reject the 
null hypotheses (time points are all equal). Multiple comparisons were adjusted by the 
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Tukey-Kramer method (ANOVA) and Dunns’ test (Friedman’s test). To adjust for 
falsely rejected null hypotheses, the Benjamin-Hochberg critical values were calculated 
(Benjamini & Hochberg, 1995) and compared with the P values from the comparison of 
proportions of pyrosequencing tags at each phylogenetic level separately. 
 
2.4 Results 
2.4.1 Qualitative assessment of the fecal microbiota 
Due to insufficient DNA material, DGGE analysis was performed in all 12 cats but only 
in 11 of the 12 dogs, while 16S rRNA gene clone libraries were constructed for 11 dogs 
and 11 cats each. In 11/12 (92%) cats and in 5/11 (45%) dogs, DGGE bands were 
observed that appeared during synbiotic administration, but were absent at baseline and 
also after discontinuation of synbiotic administration (Table 2). The DNA from these 
bands was purified and re-amplified using universal bacterial primers as described 
above. Sequencing of these amplicons identified sequences matching the 16S rRNA 
gene of Enterococcus faecium. Using 16S rRNA gene clone libraries, at least one 
probiotic species (Bifidobacterium longum, Lactobacillus acidophilus, L. plantarum, L. 
delbrueckii, or L. rhamnosus) was detected during synbiotic administration in 8/11 
(73%) cats and 9/11 (82%) dogs (Table 2), but were undetectable before or after 
synbiotic administration.    
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2.4.2. Quantitative real-time PCR 
Analysis by qPCR showed an increase in the abundance of probiotic groups in feces 
during synbiotic administration and return to baseline abundance after conclusion of 
probiotic administration (Fig. 1), as determined by increased concentrations of target 
DNA from probiotic groups. However, the increase in abundance of probiotic bacteria in 
feces differed depending on the bacterial genus. Fecal abundance of Enterococcus and 
Streptococcus spp. were found to be significantly increased in at least one time point 
during synbiotic administration when compared with baseline abundances of these 
bacteria, in both cats and dogs (Fig. 1). In cats, Lactobacillus and to a lesser extent 
Bifidobacterium spp. increased during synbiotic administration, but the difference 
among time points did not reach statistical significance, with the exception of samples 
collected on day 17 showing significantly higher counts than those in samples collected 
on day 38 (two weeks after cessation of synbiotic administration). In dogs, counts of 
fecal Lactobacillus spp. increased by day 3 of synbiotic treatment, although this 
difference was not statistically significant.  Lactobacillus spp. counts returned to 
baseline abundance values by day 8, while fecal abundance of Bifidobacterium spp. was 
not significantly altered (Fig. 1). 
 
2.4.3 Massive parallel pyrosequencing 
454-Pyrosequencing in cats. A total of 187 396 pyrosequencing reads were generated: 75 
350 at baseline, 60 355 on day five of synbiotic administration, and 51 691 on day 23 (2 
days after end of synbiotic administration). The most abundant phylum was Firmicutes   
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Fig. 1. Quantitative real-time PCR results for cats (A) and dogs (B) at baseline, during 
and after synbiotic administration. Baseline (BL), days (D) 1 or 3, 5 or 8, and 17 during 
synbiotic administration and days 23 or 26, 26 or 29, and 38 after synbiotic 
administration for all four probiotic genera: Enterococcus, Lactobacillus, 
Bifidobacterium, and Streptococcus. Error bars represent mean normalized log10 16S 
rRNA gene copies and standard deviation. † = significantly higher than baseline; ‡ = 
significantly lower than day 17 (P<0.05). 
 
 
 
followed by Actinobacteria (Fig. 2). Within these main phyla, Clostridiales, 
Lactobacillales and Erysipelotrichales (Firmicutes) and Coriobacteriales 
(Actinobacteria), were the most abundant orders (Fig. 3).  After adjustment for falsely 
rejected null hypotheses, there were no significant differences in relative proportions of 
pyrosequencing tags belonging to the phyla Firmicutes, Actinobacteria, Bacteroidetes, 
Proteobacteria, and Fusobacteria across the three time points evaluated (Supplementary 
Table A1). Also, there was no statistically significant difference in any class, order, 
family, or genus within these phyla. Based on unadjusted P values, the genus Collinsella 
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(Actinobacteria) was found to be significantly higher at baseline (median: 2.7% of all 
sequences) when compared with both during (1.7%) and after synbiotic administration 
(1.2%) (P<0.01). Also, Lactobacillus (Firmicutes) was found to be higher during 
synbiotic administration (0.4%) than before or after administration (median: 0%) 
(P<0.0390); however, multiple comparisons did not reach statistical significance. 
Differences in proportions of pyrosequencing reads among and within cats before, 
during, and after synbiotic administration were visualized by plotting a heatmap at the 
family level (Fig. 4), using a gplots library (Warnes, 2010) in the R software (R, 2004). 
These heatmaps showed a high variability among cats and a comparably much lower 
degree of variation within cats (i.e., proportions for time points within a subject were 
usually clustered together). 
 454-Pyrosequencing in dogs. A total of 201 642 pyrosequencing reads were 
generated: 87 737 at baseline, 56 852 on day five of synbiotic administration, and 57 053 
on day 23 (2 days after end of synbiotic administration). The most abundant phylum was 
Firmicutes, followed by Actinobacteria and Bacteroidetes (Fig. 2). Within these main 
phyla, Clostridiales, Erysipelotrichales, and Lactobacillales (Firmicutes), and 
Coriobacteriales (Actinobacteria) were the most abundant orders (Fig. 3). After 
adjustment for falsely rejected null hypotheses, there were no statistically significant 
differences in the relative proportions of pyrosequencing tags belonging to any 
phylogenetic level (Supplementary Table A2). Based on unadjusted P values, the 
proportion of organisms belonging to the family Eubacteriaceae (Firmicutes) was found 
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Fig. 2. Composition of the fecal bacterial microbiota for cats (A) and dogs (B) at 
baseline, during and after synbiotic administration at the bacterial phylum level. Baseline 
(BL), Day 5 during synbiotic administration, and Day 23 after synbiotic administration. 
The y axis (average percentage of sequences) was modified to show the low abundant 
phyla.  
 
 
 
Fig. 3. Composition of the fecal bacterial microbiota for cats (A) and dogs (B) at 
baseline, during and after synbiotic administration at the bacterial order level. Baseline 
(BL), Day 5 during synbiotic administration, and Day 23 after synbiotic administration. 
The y axis (average percentage of sequences) was modified to show the low abundant 
orders.  
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to be significantly increased during synbiotic administration (median: 0.38% for all 
sequences) when compared with baseline values (0.02%; P<0.05). Likewise, the 
proportion of organisms belonging to the genus Eubacterium was found to be 
significantly higher during synbiotic administration (median: 0.38% of all sequences) 
when compared to baseline results (0.02%; P<0.05). Also, the proportion of organisms 
belonging to the genus Roseburia (Firmicutes) was found to be significantly lower two 
days after cessation of synbiotic administration (median: 3.3% of all sequences) when 
compared with the proportions at both baseline (5.1%) and on day 5 of synbiotic 
administration (4.5%; P<0.05). Also, based on unadjusted P values, relative proportions 
of sequencing tags belonging to the phylum Fusobacteria and all phylogenetic levels 
down to the genus Fusobacterium were found to be significantly higher during synbiotic 
administration (median: 0.77% of all sequences) when compared to baseline values 
(0.10%; P<0.05). Differences in proportions of pyrosequencing reads among and within 
dogs before, during, and after synbiotic administration were also visualized by plotting a 
heatmap at the family level (Fig. 4). Similarly to results observed in the cats, these 
heatmaps showed a high variability among individual dogs and a comparably lower 
variation within dogs (i.e., proportions for time points within a subject were usually 
clustered together). 
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2.4.4. Principal Component Analysis (PCA)  
Principal component analysis, based on the Unifrac distance metric, did not show any 
clustering of the fecal microbiota at any time point during the study period for either cats 
or dogs (data not shown).  
 
2.4.5 Diversity indices for pyrosequencing bacterial tags  
At 1% dissimilarity, no significant differences were found between the Shannon-Weaver 
diversity indices across the evaluated time points in the dogs. Cats had a significantly 
higher Shannon-Weaver diversity index before administration of the synbiotic (mean ± 
SD: 4.9 ± 0.3) when compared to the indices at five days of feeding the synbiotic (4.3 ± 
0.6, P<0.05) or at two days after the end of administration (4.3 ± 0.6, P<0.01), 
respectively. 
 
2.4.6. Effect of the synbiotic on GI and immune function 
With the exception of one cat and one dog that vomited once during synbiotic 
administration, all enrolled animals were reported by the owners to eat and behave 
normally during synbiotic administration. Similarly, fecal consistency was reported as 
normal by the owners with the exception of two cats and two dogs that were recorded to 
have pulpy feces for two days during the administration period. No flatulence was 
recorded in any cat during the 21 days of synbiotic administration. In contrast, owners 
reported that seven dogs had some flatulence (scores: 0 = no flatulence: 5 dogs; 1= some  
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Fig. 4. Heatmap showing log2 transformed proportions of pyrosequencing tags for cats 
(A) and dogs (B) at baseline, during and after synbiotic administration at the bacterial 
family level. The ordering of the corresponding dendrogram is by the mean value of the 
rows. The identification for the subjects is shown on the right y-axis, where B, D, and A 
indicate before, during, and after synbiotic administration, respectively. Only bacterial 
families that were detected in a sample from at least one time point (before, during, or 
after synbiotic administration) in at least half of the animal subjects are shown. 
Clostridiales* in panel A indicates Clostridiales Family XIII incertae sedis. 
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flatulence: n = 7 dogs; 2 = frequent flatulence: n = 0 dogs) for at least one day during 
synbiotic administration. Other clinical signs of gastrointestinal health such as appetite, 
defecation frequency, and volume of feces in both cats and dogs were judged to be 
normal by the owners during treatment with the synbiotic (21 days). With the exception 
of lymphocytes in the cats and neutrophils in the dogs, which were decreased, although 
not significantly, during synbiotic administration, none of the evaluated serum 
(cobalamin, folate, IgA, TLI, and PLI) or fecal (IgA and α1-PI) markers of 
gastrointestinal and immune function changed significantly after three weeks of 
administration or three weeks after discontinuation of the preparation (Table 4). 
 
2.5 Discussion 
Despite the numerous applications of prebiotics, probiotics, and synbiotics in veterinary 
medicine, to date little is known about the in vivo effects of these agents on the 
composition of the intestinal microbiota of cats and dogs. Several studies have used 
traditional culture techniques to evaluate the effects of probiotics and prebiotics on fecal 
microbial composition of dogs (Swanson et al., 2002; Vahjen & Manner, 2003). Also, 
culture techniques have been used to assess the effect of fructooligosaccharides on 
duodenal bacterial populations of cats (Sparkes et al., 1998). However, it is well 
acknowledged today that traditional culture techniques have limitations in fully 
characterizing complex microbial communities (Ritz, 2007) like those found in the 
mammalian gastrointestinal tract (Eckburg et al., 2005). Molecular tools are now widely 
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Table 4 Mean concentrations (± standard deviation) of relevant blood, serum, and fecal 
markers obtained before (baseline), during (day 21), and after (day 42) synbiotic 
administration. P values are given for the comparison of means (ANOVA) or ranks 
(Friedman’s test) 
 
 
Parameters in cats Control range Baseline Day 21 Day 42 P 
Serum Cobalamin 290-1500 ng L-1 1620.0±536.7 1680.0±532.8 1657.0±582.3 0.8845 
Serum Folate   9.7-21.6 μg L-1  20.8±7.8 19.6±6.0 19.8±6.2 0.5458 
Serum fPLI  2.0-6.8 μg L-1 5.8±2.1 5.8±2.8 7.4±2.6 0.1682 
Serum fTLI  12.0-82.0 μg L-1 29.7±19.3 33.4±13.4 27.7±21.5 0.4032 
Serum IgA (mg/dl) nn 94.8±55.9 97.0±62.9 106.0±91.2 0.7979 
Total Lymphocytes 1500-7000 μL-1 4111±1924 3097±1279 3918±1589 0.0519 
Total Neutrophils 2500-12500 μL-1 3644.0±1874.0 4289.0±1693.0 4739.0±3028.0 0.2192 
Total Eosinophils <1500 μL-1 622.2±460.2 910.8±932.5 564.0±284.8 0.8302 
RBC  5-10x106 μL-1 8.8±1.3 8.5±0.9 8.7±1.2 0.4913 
Fecal α1-PI 0.04-1.6 μg g-1 2.9±2.0 2.3±2.1 2.4±1.9 0.4355 
Parameters in dogs      
Serum Cobalamin  251-908 ng L-1 562.5±199.8 595.4±186.4 597.7±170.4 0.3919 
Serum Folate  7.7-24.4 μg L-1 11.5±2.3 12.4±2.6 12.3±3.1 0.3343 
Serum cPLI (Spec 
cPL®)  
0-200 μg L-1 48.7±33.7 58.3±64.6 60.1±58. 0.8302 
Serum cTLI 5.7-45.2 μg L-1 10.2±3.2 11.7±2.4 9.9±3.9 0.3209 
Serum IgA(mg/dl) nn 53.6±52.0 65.2±62.8 63.1±59.2 0.9382 
Fecal IgA 0.22-3.24 mg g-1 1.2±0.7 1.1±1.0 1.1±0.9 0.9583 
Total Lymphocytes 1500-7000 μL-1 2172.0±1255.0 2347.0±1135.0 2643.0±1686 0.2979 
Total Neutrophils 2500-12500 μL-1 5874.0±2562.0 4306.0±2520.0 5284.0±2342.0 0.0621 
Total Eosinophils <1500 μL-1 538.5±479.3 423.2±368.7 452.7±259.0 0.3508 
RBC 5-10x106 μL-1 6.8±0.7 6.9±0.8 6.9±0.8 0.3755 
Fecal α1-PI  2.2-18.7 μg g-1 7.6±6.7 7.7±4.2 8.3±6.2 0.8438 
 
 
 
available to identify intestinal microbial phylotypes (Furrie, 2006). Molecular methods, 
such as fluorescent in situ hybridization, have been used to evaluate the effect of the 
probiotic Lactobacillus acidophilus DSM13241 on fecal bacterial populations in cats 
(Marshall-Jones et al., 2006) and dogs (Baillon et al., 2004). Also, one study has 
recently evaluated the effect of the probiotic Enterococcus faecium SF68 on fecal 
microbial diversity of cats with feline herpesvirus infection using DGGE (Lappin et al., 
2009). However, the application of traditional molecular tools to fully characterize the 
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composition of the GI microbiota can also be technically and economically challenging. 
Recently developed high throughput technologies allow a more in depth phylogenetic 
coverage of the intestinal microbiota (Zoetendal et al., 2008; Suchodolski et al., 2009) 
and thus could be useful in evaluating the overall effect of prebiotic, probiotic, or 
synbiotic formulations on intestinal microbial communities. 
This study used various complementary molecular tools to evaluate the effect of 
a synbiotic formulation on fecal bacterial composition of healthy cats and dogs. Our 
results indicate that while the administration of the multi-species synbiotic preparation 
for 21 days induced several changes in the abundance of specific probiotic groups in 
both cats and dogs, the fecal microbiota was not altered on higher phylogenetic levels as 
evidenced by 454-pyrosequencing. We observed the appearance of DGGE bands in 
11/12 cats and 5/11 dogs that were not present before or after synbiotic administration. 
Sequence analysis identified these bands as Enterococcus faecium, suggesting that these 
organisms were more abundant in feces during the ingestion of the synbiotic. Similarly 
to these results obtained with DGGE, the analysis of 16S rRNA gene clone libraries 
revealed that bacterial species contained in the administered synbiotic, such as 
Bifidobacterium longum and various Lactobacillus spp. matching those contained in the 
synbiotic formulation, were present in the feces of most cats (8/11) and dogs (9/11) 
during the administration of the synbiotic, but were undetectable at baseline or after 
administration was discontinued. This observation further suggests an increase in fecal 
abundance of the ingested probiotic organisms during the administration period. 
However, the phylogenetic coverage of 16S rRNA gene clone libraries is generally 
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limited to the species level (Suchodolski et al., 2008). Therefore, we cannot confirm if 
the appearance of the bacteria in feces were truly the ingested probiotic strains contained 
in the synbiotic, or if they belonged to the same bacterial species but were in fact 
different strains. Nonetheless, the fact that these particular species increased during the 
administration period, but were not detectable before and after the administration period 
in most of the animals, strongly suggests that the administration of the product led to an 
increase of these probiotic groups in the feces of the enrolled cats and dogs.  Of further 
interest is that the detection of the probiotic species by the 16S rRNA gene clone 
libraries was not equal among individual cats and dogs. For instance, in some animals 
only one probiotic species was detected during the administration period, while in other 
animals several probiotic species could be identified during administration of the 
synbiotic. These observations suggest a highly individualized response of the host to 
administered probiotic species.  
The fact that the probiotic groups were undetectable at baseline suggests that the 
bacterial species contained in the synbiotic were not present in the gastrointestinal tract 
of the enrolled cats and dogs. The probiotic strains in the synbiotic preparation have in 
fact been derived mostly from human and dairy sources. While it has been suggested that 
canine-derived bacterial species exhibit host specificity (McCoy & Gilliland, 2007), to 
date there are no studies confirming this assumption. In fact, probiotics may not need to 
be native to colonize the intestinal tract of the recipient host, because the adherence of 
these agents to intestinal mucus has been shown not to be host-specific (Rinkinen et al., 
2003). Furthermore, studies have shown that canine-derived probiotic strains can 
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successfully transit the murine gastrointestinal tract (O'Mahony et al., 2009) and can 
adhere to both human and canine intestinal mucus in a similar fashion (Strompfova et 
al., 2004).  To our knowledge there are only a few probiotic strains that have been 
derived from dogs (Strompfova et al., 2004; Biagi et al., 2007; McCoy & Gilliland, 
2007, O'Mahony et al., 2009; Martin et al., 2010), and no feline-specific probiotic 
strains have been described in the literature to date.  
Similarly to the findings using DGGE and 16S rRNA gene clone libraries, 
quantitative real-time PCR analyses showed increases in fecal abundance of probiotic 
bacterial groups within a few days after the subjects started consuming the synbiotic 
preparation (Fig. 1), with abundances returning to baseline levels after discontinuation of 
synbiotic administration. Several studies in humans have shown that qPCR can be useful 
in detecting quantitative increases of ingested probiotics in feces (Bartosch et al., 2005; 
Vitali et al., 2010), although an inter-individual host response to the dietary intervention 
is frequently noticed. This variation among subjects was also noticeable in our study, as 
evidenced by the wide variability in fecal abundances of the target groups within each 
time point (Fig. 1). Interestingly, in the current study the observed quantitative increases 
also varied among the four bacterial genera contained in the synbiotic preparation. The 
fecal abundance of Lactobacillus and Bifidobacterium spp. was not significantly 
increased during synbiotic administration, while abundances of Enterococcus and 
Streptococcus spp. were significantly increased during at least one time point during 
synbiotic administration in both cats and dogs. This observation is likely due to the 
unequal proportions of each probiotic strain contained in the synbiotic preparation 
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evaluated. It is common for commercially available multi-species probiotic formulations 
to contain unequal quantities of microorganisms. For instance, a multi-species probiotic 
for use in humans (VSL#3, VSL Pharmaceuticals) is known to contain different 
concentrations of at least one probiotic strain (Pagnini et al., 2010). 
In spite of the observed increases of the ingested probiotic groups in feces using 
DGGE, 16S rRNA gene clone libraries, and qPCR, pyrosequencing of the 16S rRNA 
gene did not reveal major changes in the proportions of the most abundant fecal bacterial 
phyla such as Firmicutes, Actinobacteria, Bacteroidetes, Proteobacteria, and 
Fusobacteria (Supplementary Tables A1 and A2). This observation is in agreement with 
other studies showing that ingestion of probiotics leads to fecal colonization by the 
ingested groups but does not alter the major bacterial groups in the intestine (Venturi et 
al., 1999). This may be due in part to the low abundance of the targeted probiotic groups 
(i.e., Lactobacillus, Bifidobacterium, Enterococcus, and Streptococcus spp.), as 
representatives of these groups accounted for less than 1% of all identified sequences in 
both cats and dogs at baseline (Supplementary Tables A1 and A2). Also, the effect of 
probiotic/prebiotic formulations on the intestinal tract may be more evident at the 
functional level (i.e., production of lactic acid and/or short chain fatty acids) rather than 
or in addition to changes in the abundance of intestinal microbial groups. For example, it 
has been shown that as low as 0.2 or 0.4% of inulin or short-chain FOS can be effective 
at modifying fecal concentrations of short-chain fatty acids in dogs, while minimally 
altering the abundance of fecal bacterial populations (Barry et al., 2009). Also, in 
humans, the ingestion of two probiotic strains (i.e., Lactobacillus helveticus Bar13 and 
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Bifidobacterium longum Bar33) led to significant increases of acetic and valeric acids 
but did not modify the overall structure of the fecal microbiota, as assessed by DGGE 
(Vitali et al., 2010). More studies are needed to investigate the effect of synbiotics on the 
functional (metabolic) activities of the GI microbiota as a supplement to phylogenetic 
analysis.  
For pyrosequencing analysis, we selected day 5 and day 23 because, based on 
DGGE and qPCR results, we expected eventual changes in the microbiota to occur quite 
rapidly (within 2-3 days) after beginning the administration of the synbiotic and after 
discontinuation of treatment. However, it is possible that alterations in the microbiota in 
response to synbiotics require several days, and by selecting days that were close to the 
transition periods we may have missed some changes that may have occurred past the 
analyzed time points. Ideally multiple days should be analyzed by sequencing to detect 
temporal changes in the microbiota. As sequencing costs continue to decrease, such 
multiple samplings could be performed in future studies.  
In this study we also showed that 21 days of oral administration of a synbiotic 
preparation did not lead to adverse gastrointestinal effects and may not interfere with 
markers of gastrointestinal (e.g., serum cobalamin and folate concentrations) or immune 
(e.g., fecal and serum IgA concentration) function. Similarly, one study showed that the 
administration of the probiotic Enterococcus faecium SF68 for six weeks did not change 
fecal IgA concentrations in adult dogs with chronic giardiasis (Simpson et al., 2009). In 
contrast, an increase in fecal IgA in young dogs has been described after oral 
administration of the same probiotic strain (i.e., E. faecium SF68), although this effect 
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was only evident after 30 weeks of probiotic administration (Benyacoub et al., 2003). 
Possible explanations for the discrepancy between this study and our investigation may 
include a shorter period of probiotic administration (3 versus 30 weeks) and also a more 
age-heterogeneous group of individuals, as age-related differences in immunological 
parameters have been observed in both cats (Campbell et al., 2004) and dogs (Blount et 
al., 2005).  
Limitations of this study include the fact that each individual animal was fed a 
different diet, lived in a different environment, and/or received the formulation in a 
different manner, all factors that could have potentially influenced our ability to detect 
major alterations in the fecal microbiota due to the administration of probiotics. 
Moreover, all animals were fed the same dose of probiotic bacteria (5x109 cfu) with no 
regards to differences in body weight (for example the body weight among the dogs 
differed up to 8-fold). While there is growing evidence suggesting a dose-dependent 
clinical effect of probiotics (Pagnini et al., 2010), to our knowledge no information 
about the efficacy of various doses of synbiotic have been published for dogs and cats. 
While preliminary data in our laboratory suggest that the body weight of dogs may not 
be a significant predictor to forecast an increased abundance of ingested probiotics in the 
feces (unpublished observations), clearly more studies are needed to evaluate if there is a 
dose-dependent effect of synbiotics on the microbiome of dogs and cats. Also, the 
separate contribution of each component in the synbiotic preparation (i.e., prebiotics and 
probiotic bacteria) to the changes observed in the fecal bacterial populations was not 
assessed independently. This is important because it has been shown in both humans 
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(Worthley et al., 2009) and dogs (Swanson et al., 2002) that the probiotic and the 
prebiotic component of a synbiotic formulation, when administered separately, may have 
different effects on fecal bacterial populations. Finally, molecular methods generally 
cannot confirm the viability of bacteria, and therefore it is possible that the isolated fecal 
bacterial DNA belonged to both viable and non-viable microorganisms (Palka-Santini et 
al., 2003). 
In summary, this study shows that oral administration with the multi-species 
synbiotic Proviable®-DC leads to increased concentrations of probiotic bacteria in the 
feces of healthy cats and dogs. Moreover, the results add to the increasing body of 
literature showing that probiotics and prebiotics may not lead to significant changes in 
the abundance of major intestinal bacterial groups of healthy animals. Further studies are 
warranted to assess the effects of the investigated synbiotic formulation on the intestinal 
microbiota of animals with gastrointestinal disease. 
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3. IN VIVO PREDICTORS OF INTESTINAL COLONIZATION BY INGESTED 
PROBIOTIC BACTERIA IN HEALTHY CATS AND DOGS 
 
3.1  Overview 
A better understanding of host-microbe interactions has the potential to improve the use 
of beneficial probiotic microorganisms to treat gastrointestinal disorders. This study 
analyzed the effect of age, bodyweight, and baseline fecal concentrations of related 
probiotic bacterial genera, as potential in vivo predictors of intestinal colonization by 
ingested probiotic microorganisms. Privately-owned healthy cats (n=12) and dogs 
(n=12) of different ages and breeds were enrolled. A multi-species synbiotic formulation 
(containing 5x109 cfu of seven probiotic bacteria, and a blend of arabinogalactans and 
fructooligosacharides) was administered daily for 21 days. Fecal samples were obtained 
before synbiotic administration (baseline samples), and every 3 to 4 days during and up 
to three weeks after synbiotic administration.  
As assessed by quantitative real-time PCR targeting the 16S rRNA gene, cats 
having a lower abundance of fecal probiotic genera at baseline had a higher fecal 
abundance of probiotic genera during the administration period when compared to the 
period after administration of probiotics. In contrast, cats having a higher fecal 
abundance of probiotic genera at baseline showed a similar abundance of probiotic 
genera during and after the administration period. Older cats may also have a higher 
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abundance of probiotic genera during the administration period when compared to the 
period after administration. Body weight was not a significant predictor in the cats. Age, 
body weight, and baseline bacteria were not significant predictors in the dogs. More 
research is needed to confirm these results using other probiotic formulations and to 
identify further predictors to forecast colonization outcomes by ingested probiotics.  
 
3.2  Introduction 
Probiotics are live microorganisms, which when administered in adequate amounts may 
confer a health benefit on the host (FAO, 2002) by enhancing immune responses 
(Pagnini et al., 2010), displacing intestinal pathogens (Lee et al., 2003), and/or 
producing antimicrobial substances (Jones & Versalovic, 2009). Because of these 
properties, the use of probiotics is gaining popularity for both the prevention and 
treatment of a variety of diseases in humans (Gareau et al., 2010) and also in veterinary 
species (Callaway et al., 2008). The success of probiotics in promoting health is thought 
to depend on an increased abundance of these agents in the intestinal tract after 
administration (Kailasapathy & Chin, 2000), a hypothesis that has led to the 
investigation of the survival and intestinal colonization properties of probiotic 
microorganisms (Bezkorovainy, 2001; Valeur et al., 2004). 
The intestinal microbiota of cats and dogs has been studied in some detail 
(Suchodolski, 2010; Handl et al., 2011). As in other animal species, probiotics are also 
increasingly being used in cats and dogs in an effort to increase the abundance of 
beneficial microorganisms in the intestinal tract. Although several investigations have 
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evaluated the in vivo effect of probiotics on the intestinal microbiota of dogs (Swanson 
et al., 2002; Manninen et al., 2006; Biagi et al., 2007; O'Mahony et al., 2009) and cats 
(Marshall-Jones et al., 2006; Veir et al., 2007; Lappin et al., 2009), the possibility of 
predicting colonization outcomes after ingestion of probiotics has not been explored in 
these animal species. This is important because an improved understanding of host-
microbe interactions has the potential to improve the therapeutic use of probiotics to 
treat disorders of the GI tract, such as inflammatory bowel disease (Shanahan, 2004). 
Here we investigated the effect of three potential in vivo predictors of intestinal 
colonization by ingested probiotic bacteria in healthy cats and dogs. Additionally, and 
because this is the first attempt to identify in vivo predictors of intestinal colonization by 
probiotics in cats and dogs, we built upon the obtained results and investigated in dogs 
quantitative fluctuations of fecal bacteria shed in feces over time, and the relationship 
between the body weight and the amount of feces excreted, as plausible hypotheses that 
may partly explain our findings.  
 
3.3 Materials and methods 
3.3.1 Probiotic study protocol 
The study protocol was reviewed and approved by the Clinical Research Review 
Committee of Texas A&M University (CRRC#07-38). Written consent was obtained 
from the owners of all enrolled animals. 
Privately-owned clinically healthy pet cats (n=12) and dogs (n=12) of different 
breeds were prospectively enrolled. On average, cats were 2.8 years old (median: 2.0, 
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range: 0.6-7.6 years old) and weighted 4.9 kg (median: 5.0, range: 3.8-5.9 kg); dogs 
were 3.8 years old (median: 3.4, range: 0.6-10.5 years old) and weighted 21.1 kg 
(median: 26.1, range: 4.6-36.9 kg). Naturally passed fecal samples were obtained by the 
owners (mainly students of Veterinary Medicine at Texas A&M University) before 
starting the study (baseline samples). Then dogs and cats received one capsule of 
Proviable®-DC (Nutramax Laboratories, Inc.) orally at home once daily for 21 days. 
Proviable®-DC is a synbiotic formulation for use in cats and dogs containing a blend of 
fructooligosaccharides, arabinogalactans, and a minimum of 5x109 cfu probiotic bacteria 
(Table 1). The proportions of each probiotic strain in Proviable®-DC are proprietary. In 
an effort to mimic a real-life situation where owners administer the probiotic preparation 
at home, owners were allowed to administer the capsule directly in the mouth, mix the 
capsule into the food, or open the capsule and mix the synbiotic preparation into the 
food, depending on the particular manner their pets generally accept oral medications. 
Additional fecal samples were collected every 3-4 days during and after probiotic 
administration until day 42 (three weeks after cessation of the administration of the 
probiotic formulation).  
 
3.3.2 DNA extraction and quantitative real-time PCR analysis 
Fecal samples (~1 gram) were collected and stored at -20°C until analysis. DNA was 
extracted from a 100 mg aliquot of each fecal sample using a bead beating phenol-
chloroform-based method described in detail elsewhere (Suchodolski et al., 2008). Fecal 
abundance of the four bacterial genera contained in the probiotic preparation (i.e., 
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Enterococcus, Streptococcus, Lactobacillus, and Bifidobacterium spp.) were estimated 
using SYBR-based (Biorad Laboratories) quantitative real-time PCR (qPCR) using a 
commercial real-time PCR thermocycler (iCycler iQ, Biorad Laboratories) and 
previously published oligonucleotide primers (Table 3). Standard curves using five 1:10 
dilutions of DNA (ranging from 2.0 ng to 0.2 pg) from lyophilized bacterial species of 
each genus and canine fecal DNA for universal bacteria were used to calculate the 
unknown bacterial genomic targets. All samples and standards were run in duplicate 
fashion. Care was taken to minimize inter-assay variability by amplifying all samples 
from a given animal subject (baseline sample, samples collected during the 
administration period, and samples collected after probiotic administration) in the same 
96 well PCR plate. The PCR mixtures (25 µl) contained 12.5 µl of iQTM SYBR® Green 
Supermix (100 mM KCl, 40 mM TRis-HCl pH 8.4, 0.4 mM of each dNTP, 50 units/ml 
of iTaq DNA polymerase, 6mM MgCl2, SYBR Green I, and 20 nM fluorescein, Biorad 
Laboratories), 9.7 μl of sterile water, 0.4 μl of each primer (final concentration: 160 nM) 
and 2 μl of DNA (~ 5 ng/μl). After the PCR was finished, a melt-curve profile was 
generated to analyze the specificity of the primers. Expected length of the amplicons was 
verified using agarose gel electrophoresis.  
 
3.3.3 Statistical analysis 
Statistical analysis was performed using SAS® 9.2 with Enterprise Guide® 4.2. For all 
analyses, we used normalized log10 16S rRNA gene copies (log10 16S rRNA gene copies 
from each particular bacterial genus divided by the log10 16S rRNA gene copies from all 
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bacteria) as our dependent variable to account for variations in total bacterial DNA 
obtained during the extraction procedure (Frank et al., 2007). In order to perform the 
analysis, raw data was organized separately for dogs and cats, and a new variable 
“bacterial group” was created for each animal species to indicate which bacterial genus 
each observation related to. This approach resulted in the creation of a total of 288 
observations for cats and 278 observations for dogs (qPCR results for Streptococcus spp. 
for one canine subject (all time points) and one time point from three other dogs were 
not available because of lack of DNA samples  and were treated as missing values).  The 
variable “time” was treated as a fixed variable with six levels (days 1, 8, and 17 during, 
and days 26, 29, and 38 after probiotic administration in cats, and days 3, 5, and 17 
during, and days 23, 26, and 38 after probiotic administration in dogs). Statistical models 
were built separately for cats and dogs. An example of a full statistical model as well as 
the corresponding SAS code is available upon request.  
Additionally, we also investigated the effect of the covariates age and body 
weight when baseline bacteria is included as the first time point (day 0) instead of as a 
covariate, resulting in time having seven levels. Based on the nature of the data (time 
points being unequally spaced but same across subjects), three covariance structures 
were attempted: Compound Symmetry (CS), Heterogeneous Compound Symmetry 
(CSH), Spatial Exponential (SPexp), as well as using no repeated statement in the 
MIXED procedure. The final covariance structure was chosen based on the Bayesian 
Information Criterion (lower is better). Model diagnostics showed that the studentized 
residuals seemed to be random and had a distribution very close to normal for both cats 
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and dogs, thus indicating valid models. Backward variable selection was performed as 
the next step by removing non significant terms (P>0.05) one by one. All post-test 
comparisons were adjusted by the Tukey-Kramer method. Restricted/residual maximum 
likelihood was used for all final analyses. A P value of less than 0.05 was considered 
statistically significant. 
 
3.3.4 Quantitative fluctuations of fecal bacteria over time 
To investigate quantitative fluctuations of fecal bacteria shed in feces over time among 
dogs of different ages, we collected one naturally passed fecal sample from five 
consecutive days (one stool per day) from a total of 22 clinically healthy dogs of 
different breeds: 10 dogs younger than five years old (median: 1.7 years, range: 3 
months to 3.8 years), and 12 dogs older than five years old (median: 8.3 years, range: 
5.9-12 years). DNA extraction and qPCR were performed as described above. We 
analyzed the fecal abundance of the genus Enterococcus because in our experience this 
bacterial group can be found in detectable concentrations by qPCR in the feces of most 
dogs. 
 
3.3.5 Relationship between the body weight and the amount of feces excreted  
To investigate the relationship between the amount of feces excreted and the 
bodyweight, we collected the total amount of one naturally passed fecal sample per day 
from two to three consecutive days (one stool per day) from 15 clinically healthy dogs of 
different breeds with a median bodyweight of 19.5 kg (range: 2.1-33.6 kg). Fecal 
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samples were weighed and these weights were used to calculate the mean amount of 
feces (grams of wet weight) excreted per day.  
 
3.4 Results 
3.4.1 Results for cats 
Using baseline bacterial abundance of related probiotic genera as a predictor, at least one 
time point and one bacterial group were different from the others (P<0.0001 and 
P=0.0099, respectively), and there was a significant interaction between baseline and 
time (P<0.0001), indicating that the differences in fecal abundance of probiotic genera 
among time points differed upon different baseline values. Cats that had a lower baseline 
abundance of related probiotic genera before starting to consume the probiotics had a 
higher abundance of the fecal probiotic genera during probiotic administration when 
compared with the post-administration period (Fig. 5). In contrast, cats that had a higher 
baseline abundance of these bacteria also had a similar abundance of probiotic genera 
both during and after the administration period (Fig. 5). Moreover, there was a 
significant interaction between baseline and bacterial group (P=0.0272), indicating that 
the baseline effect was different in at least one of the bacterial genera contained in the 
probiotic formulation (Fig. 6). Age and bodyweight were not significant predictors.  
 Using baseline bacterial abundance of related probiotic genera as a response (day 
0), at least one time point and one bacterial group were different from the others 
(P=0.0011 and P<0.0001, respectively), as before. Also, there was an interaction 
between age and time (P=0.0291), indicating that the differences in fecal abundance of 
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probiotic genera differed based on the age of the cats. Older cats had a higher fecal 
abundance of probiotic genera during the consumption of probiotics when compared 
with the period after administration (Fig. 7). However, after removing the oldest cat 
from the statistical analysis, the age was no longer a significant predictor. As before, 
bodyweight was not a significant predictor.  
 
 
 
Fig. 5. Effect of baseline fecal abundance of probiotic bacterial genera on the abundance 
of these bacteria during and after synbiotic administration in cats. Days 1, 8, and 17 
during synbiotic administration, Days 26, 29, and 38 after synbiotic administration. The 
dots in the graph represent the abundance of all probiotic genera in feces, as determined 
by qPCR. Cats that had a lower fecal baseline abundance of the probiotic genera (x axis) 
had a higher abundance of the probiotic genera during synbiotic administration (days 1, 
8 and 17) when compared to the period after administration (days 26, 29, and 38). 
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3.4.2 Results for dogs 
Using baseline bacterial abundance of related probiotic genera as a predictor, at least one 
time and one bacterial group were different than the others (P=0.0003 and P<0.0001, 
respectively). Differences of least squares means revealed that the fecal abundance of 
probiotic species on day 3 were higher than on day 26 (P=0.0004) and day 38 
(P=0.0008). Although fecal colonization with the probiotic preparation was also affected 
by the bacterial group administered (P<0.0001), multiple comparisons among the 
different bacterial groups were not performed because the results from different qPCR 
assays are not directly comparable to each other. The estimate for the common slope for 
the effect of baseline bacteria (0.21 ± 0.07) was significantly different from zero 
(P=0.0023), suggesting a positive relationship between the fecal bacterial abundance of 
related probiotic genera at baseline and at subsequent time points during and after 
probiotic administration. Age and bodyweight were not significant predictors.  
 Using baseline bacterial abundance of related probiotic genera as a response (day 
0), at least one time point and one bacterial group were different than the others 
(P<0.0001 and P<0.0001, respectively), as before. Differences of least squares means 
revealed that probiotic genera on day 3 during probiotic administration were higher than 
those at baseline (P=0.0005), on day 26 (P=0.0002), or on day 38 (P=0.0004). As 
before, age and bodyweight were not significant predictors. 
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Fig. 6. Effect of baseline fecal abundance of probiotic bacterial genera on the abundance 
of these bacteria at all subsequent time points in cats. With the exception of the genus 
Enterococcus, there was a positive linear relationship between the abundance of 
probiotic genera at baseline (x axis) and the abundance of these bacteria at all 
subsequent time points.  
 
 
 
3.4.3 Quantitative fluctuations of fecal bacteria over time 
Using two-tailed unpaired Student’s t test for groups with unequal variances, there was 
no significant difference in the fecal abundance of Enterococcus between the two age 
groups (younger and older than five, P=0.6966). Also, there was no difference in the 
percentage coefficient of variation (P=0.1783) and in the population variability 
(P=0.2313) across the 5 sampled days between the two age groups. Unexpectedly, 
however, there was a marginally significant difference in the standard deviations across 
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the five sampled days between the younger (mean standard deviation: 0.24 ± 0.14) and 
the older (mean standard deviation: 0.15 ± 0.07) group of dogs (P=0.0618).  
 
 
 
 
Fig. 7. Effect of age on fecal abundance of probiotic bacterial genera at baseline, during 
and after synbiotic administration in cats. Baseline (day 0), during synbiotic 
administration (days 1, 8, and 17) and after administration (days 26, 29, and 38). 
Although the divergence of the regression lines suggests that age can be a significant 
factor to explain difference in fecal abundance of the probiotic genera during and after 
synbiotic administration, this effect was mainly related with the oldest cat. 
 
 
 
3.4.4 The relationship between the bodyweight and the amount of feces excreted 
The total amount of a total of 35 fecal samples from 15 dogs was weighed and these 
weights were used to calculate the mean amount of feces (grams of wet weight) excreted 
per day. This mean (in grams) was plotted against the bodyweight in kilograms (Fig. 8). 
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There was a significant positive linear relationship between bodyweight and the amount 
of feces excreted (P=0.0001). The 90% predictive interval of this relationship was ~ 70 
grams of feces.  
 
 
 
 
Fig. 8. Linear relationship between the body weight (in kilograms) of dogs and the 
amount of feces excreted (in grams, wet weight). Error bars represent mean with 
standard deviation. Dashed lines represent the 90% confidence interval of the linear 
slope. 
 
 
 
3.5 Discussion 
Increasing evidence suggests that ageing may be associated with changes in the 
composition of the intestinal microbiota (Woodmansey, 2007), but the role of age on 
colonization outcomes by ingested probiotics has rarely been explored. A recent study 
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showed, using microbial microcosms, that when the communities in an ecosystem are 
highly uneven, or there is dominance by one or a few species, the function of the 
ecosystem as a whole is less resistant to environmental stress (Wittebolle et al., 2009). 
This observation led us to speculate that the opposite may also be true: that a stable 
ecosystem (the intestinal microbiota) will contain steady bacterial numbers over time, 
and may therefore be less likely to change (e.g. less prone to displacement and/or 
competition by probiotic bacteria). Hence, we hypothesized that dogs of different age 
would excrete similar amounts of fecal bacterial organisms over time (i.e. would have a 
stable intestinal microbial ecosystem over time regardless of the age) because if true, this 
may help explain the observed non-significant effect of age as a predictor of colonization 
by the ingested probiotics in the dogs. In contrast to our original hypothesis, however, 
the findings suggest that fecal shedding of Enterococcus over a period of five days may 
be more variable in dogs younger than five years old when compared with dogs older 
than five. However, this observation may or may not apply to other members of the fecal 
microbiota. Also, it has been shown in dogs that age-related changes in the relative 
proportions of intestinal bacterial groups coincide with changes in diet and physiological 
processes (Buddington, 2003) and dogs of different age are known to harbor different 
microbial populations, especially in the large intestine (Benno et al., 1992). More 
research is needed to investigate the effect of age on intestinal colonization outcomes by 
ingested probiotics. 
 The finding that the bodyweight of the dogs was not a significant predictor of 
colonization by the ingested probiotics was interesting because one would expect that 
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heavier (bigger) dogs would defecate proportionally a higher amount of feces than 
lighter (smaller) dogs. More importantly, most investigations have shown that while the 
consumption of probiotics leads to increased concentrations in the feces, these increases 
generally disappear within days after ending its administration (Tannock et al., 2000; 
Baillon et al. 2004; Elli et al., 2006), suggesting that the presence of probiotics in feces 
is merely due to the excretion of the ingested microorganisms. Thus, we hypothesized 
that if bodyweight correlates with the amount of feces excreted, an ingested probiotic 
mixture could also be more or less diluted in feces depending on the bodyweight of the 
animal, and this parameter could be used to predict fecal colonization by ingested 
probiotics. The findings showed that indeed there is a positive relationship between the 
bodyweight and the amount of feces excreted, but the 90% predictive interval was found 
to be considerably large (about 70 grams of feces). This was partly due to the wide day-
to-day variation in the amount of feces excreted in six out of the 15 dogs.  Interestingly, 
the owners of five of these six dogs revealed that their pets eat a fixed amount of food 
per meal and also a fixed amount of meals per day. Hence, these results suggest that 
dogs excrete variable amounts of feces every time, depending on their unique 
metabolism. Therefore, we propose that the same dose of ingested probiotics (e.g. 5x109 
cfu) may not get diluted in feces proportionally to the bodyweight of the dog, and this 
may partly explain the observed non-significant effect of bodyweight as predictor of 
fecal colonization in the probiotic study. In this study, however, we did not investigate 
whether the relationship between bodyweight and feces excreted can be extrapolated to 
the actual numbers of fecal bacteria. Also, bodyweight may not be an accurate parameter 
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to estimate the size of an animal. Other parameters to estimate the size of an animal (e.g. 
height at the cross and/or length of body) would be interesting to investigate as potential 
predictors of fecal colonization by ingested probiotics. 
 The effect of native intestinal microbial populations on colonization outcomes by 
ingested probiotics is an interesting phenomenon rarely discussed in the literature. 
Stecher et al. (2010) reported that mice with a high abundance of fecal Lactobacillus 
spp. were more efficiently colonized by a commensal Lactobacillus reuteri strain after 
oral inoculation. However, this conclusion was based only on a linear relationship 
between fecal Lactobacillus at baseline (i.e. before oral inoculation) and fecal L. reuteri 
after oral inoculation. A similar linear relationship was also found in the current study 
between the fecal concentrations of probiotic genera at baseline and during all 
subsequent time points during and after probiotic administration (Fig. 6). However, in 
this study this observation only reflects that cats that had a lower fecal bacterial 
abundance at baseline also maintained a lower fecal bacterial abundance during and after 
probiotic administration, and cats that had a higher fecal bacterial abundance at baseline 
also maintained a higher bacterial abundance during and after administration of the 
probiotic (Fig. 6). Here, we investigated beyond this observation and showed that fecal 
abundance of the ingested probiotic genera was higher in cats that had a lower fecal 
baseline abundance of related bacteria (Fig. 5). Others have also suggested that intestinal 
colonization by probiotic bacteria may be higher in subjects having lower concentrations 
of these bacteria before ingestion of probiotics (Vitali et al., 2010). Indeed, more 
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research is needed to study the effect of native intestinal microbial populations on 
colonization outcomes by ingested probiotics. 
 Finally, in this study the animals were fed different diets and received the probiotic 
preparation in a different manner, variables that could have influenced our ability to 
identify a significant effect of the investigated predictors. However, the study design was 
intended to mimic a real-life scenario where owners administer probiotics at home and 
therefore our results may still hold relevant to the veterinary field.  The prebiotic 
components in the synbiotic formulation could also have had an effect on the 
quantitative changes observed in fecal bacteria (Worthley et al., 2009), but this effect 
could not be tested separately in this study.  
In summary, cats having a lower fecal abundance of related probiotic genera 
before consuming probiotics may have a higher fecal abundance of ingested probiotics 
during consumption of these agents. The body weight was not a significant predictor of 
colonization in the dogs, maybe due to the wide variation in the linear relationship 
between bodyweight and the amount of feces excreted. The age in cats may also 
influence colonization outcomes by ingested probiotics but more studies are needed to 
confirm this effect. 
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4. THE EFFECT OF THE PROTON-PUMP INHIBITOR OMEPRAZOLE ON 
GASTROINTESTINAL BACTERIA OF HEALTHY DOGS 
 
4.1  Overview 
The effect of a proton-pump inhibitor on gastrointestinal microbiota was evaluated. 
Eight healthy 9-month-old dogs (4 males and 4 females) received omeprazole (1.1 
mg/kg) orally twice a day for 15 days. Fecal samples and endoscopic biopsies from the 
stomach and duodenum were obtained on days 30 and 15 before omeprazole 
administration, on day 15 (last day of administration), and 15 days after administration. 
The microbiota was evaluated using 16S rRNA gene 454-pyrosequencing, fluorescence 
in situ hybridization, and qPCR. In the stomach, pyrosequencing revealed a decrease in 
Helicobacter spp. during omeprazole (median 92% of sequences during administration 
compared to >98% before and after administration; p=0.0336), which was accompanied 
by higher proportions of Firmicutes and Fusobacteria. FISH confirmed this decrease in 
gastric Helicobacter (p<0.0001) and showed an increase in total bacteria in the 
duodenum (p=0.0033) during omeprazole.  However, Unifrac analysis showed that 
omeprazole administration did not significantly alter the overall phylogenetic 
composition of the gastric and duodenal microbiota. In feces, qPCR showed an increase 
in Lactobacillus spp. during omeprazole (p<0.0001), which was accompanied by a lower 
abundance of Faecalibacterium spp. and Bacteroides-Prevotella-Porphyromonas in the 
male dogs. This study suggests that omeprazole administration leads to quantitative 
changes in gastrointestinal microbiota of healthy dogs.  
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4.2 Introduction 
The secretion of gastric acid is one of the first defense mechanisms in the body to avoid 
the introduction of potentially harmful infectious agents into the intestinal tract. Gastric 
acid is secreted by the parietal cells and is regulated by complex paracrine, endocrine, 
and neural pathways (Yao & Forte, 2003). 
Proton pump inhibitors (PPIs) are compounds of widespread therapeutic use in 
human and veterinary medicine. PPIs inhibit the secretion of gastric acid by blocking the 
H+/K+-ATPase in gastric parietal cells (Howden et al., 1984, Sachs et al., 1995). In 
humans, a recent retrospective study of 125 patients showed that advanced age, low 
serum albumin concentrations, and concomitant use of PPIs were significant risk factors 
for Clostridium difficile-associated diarrhea (Kim et al., 2010), an important disease with 
increasing rates of mortality (Dawson et al., 2009). Likewise, a recent study involving 
5,387 elderly subjects, and a systematic review of 2,948 patients, has linked the use of 
PPIs with an increased risk of diarrhea (Pilotto et al., 2008), and a higher risk of enteric 
infections (Leonard et al., 2007), respectively.   
The mechanisms by which the suppression of gastric acid secretion predisposes 
patients to an increased risk of gastrointestinal (GI) disease are not well understood. For 
example, while there is mounting evidence suggesting an association between the use of 
PPIs and C. difficile-associated disease (Dial, 2009, Pant et al., 2009), gastric acid does 
not kill C. difficile spores (Rao et al., 2006), which are believed to be crucial for the 
transfer of the microorganism (Dawson et al., 2009). Also, a large case-control cohort 
study of more than 170,000 users of acid-suppressing drugs, including PPIs, showed no 
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association of antacid use with bacterial gastroenteritis (Garcia Rodriguez & Ruigomez, 
1997) and a recent review of the literature indicates that bacterial overgrowth during 
PPIs administration rarely leads to clinical disease (Williams & McColl, 2006). These 
observations illustrate the possibility that the development of GI disorders in patients 
that are treated with gastric acid inhibitors is a multi-factorial phenomenon rather than an 
isolated association (Canani & Terrin, 2010).   
The GI tract of mammals is home to a vast number of different microbial groups, 
all acting in close symbiosis with one another and with their host (Neish, 2009).  Despite 
the widespread medical use of PPIs and its potential involvement in intestinal dysbiosis 
(Vesper et al., 2009), only a few studies have explored the effect of these compounds on 
GI microbial communities, mainly using culture techniques for specific microorganisms 
(e.g. Helicobacter pylori) (Sharma et al., 1984, Fried et al., 1994, Saltzman et al., 1994, 
Verdu et al., 1994, Logan et al., 1995, Thorens et al., 1996). However, culture 
techniques are by definition restricted to cultivable microorganisms, a group 
representing an insignificant proportion of all GI microbiota (Eckburg et al., 2005, 
Rajilic-Stojanovic et al., 2007). Culture independent, 16S rRNA gene-based techniques 
have greatly enhanced our knowledge of intestinal microbial inhabitants, but these 
techniques have rarely been used to evaluate the effect of gastric acid inhibition on the 
overall composition of the GI bacterial microbiota (Williams & McColl, 2006, Vesper et 
al., 2009).  
As in humans, PPIs and other inhibitors of gastric acid secretion are frequently 
used in dogs with disorders of the upper GI tract. However, the effect of omeprazole or 
 68
any other suppressor of gastric acid secretion on the GI bacterial microbiota of dogs has 
not been investigated and was the primary objective of this study. 
 
4.3 Materials and methods 
4.3.1 Study design 
Eight intact clinically healthy mixed-breed dogs, four male and four female, were 
entered into this study. All dogs were nine months old, of similar weight (18.6 ± 2.0 kg) 
and were fed once a day a commercial diet (8755 Teklad: 21% protein, 4% fiber, 
Harlan). Omeprazole capsules (Zegerid, Santarus) were administered orally at an 
average dose of 1.1 ± 0.1 mg/kg twice a day (8 am and 8 pm) for 15 days. Immediately 
after administration of omeprazole, all dogs were given 20 ml of water orally. Multiple 
mucosal biopsy specimens from the gastric body and the proximal duodenum (12-15 
from each site) were obtained from all dogs on Days 30 (Day -30) and 15 (Day -15) 
before omeprazole administration, on the last day of omeprazole administration (Day 
15), and 15 days after the end of omeprazole administration (Day 30). Biopsies were 
collected by endoscopy under general anesthesia (sedation with butorphanol 0.2 mg/kg 
IM 15 minutes before induction with thiopental IV 15 mg/kg followed by endotracheal 
intubation and maintenance of anesthesia with sevoflurane in 100% oxygen via a circle 
system). For both stomach and duodenum, 3 biopsies were flash frozen in liquid nitrogen 
for DNA extraction, and 6-7 biopsies were harvested and placed into 10% formalin for 
FISH analysis and histological assessment according to the guidelines of the World 
Small Animal Veterinary Association (Day et al., 2008). Gastric juice (~2 mL) was 
 69
obtained before each endoscopic procedure via an endoscopic catheter and the pH 
measured immediately with a pH paper (EMD Chemicals) and a pH meter. Fecal 
samples were collected by rectal palpation on Days -30, -15, 15, and 30, and stored at -
80 °C until analysis. The study protocol was approved by the Institutional Animal Care 
and Use Committee of the University of Illinois (approval number: 08261). 
 
4.3.2 DNA extraction  
Genomic DNA was extracted from the biopsies and feces using a bead-beating phenol-
chloroform method as described elsewhere (Suchodolski et al., 2010).  
 
4.3.3 Massive parallel 454-pyrosequencing 
The gastric and duodenal mucosa-adherent microbiota were evaluated using 
pyrosequencing of samples collected on Days -30 and -15 (before omeprazole 
administration), on Day 15 of omeprazole administration, and on Day 30 (after 
discontinuation of omeprazole administration) using a bacterial tag-encoded FLX-
Titanium 16S rRNA gene amplicon pyrosequencing (bTEFAP) as described previously 
for canine intestinal samples (Handl et al., 2011). Sequences with identity scores to 
known or well characterized 16S rRNA gene sequences greater than 97% identity (< 3% 
divergence) were resolved at the species level, between 95% and 97% at the genus level, 
between 90% and 95% at the family level, and between 80% and 90% at the order level.  
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4.3.4 Quantitative real-time PCR (qPCR)                                                                                                  
The abundance of total bacteria, Helicobacter, Lactobacillus, and Enterococcus was 
estimated by qPCR in the obtained DNA samples from the gastric and duodenal biopsies 
using published oligonucleotides (Supplementary Table A3). TaqMan reaction mixtures 
(total 10 μL) contained 5 μL of TaqMan® Fast Universal PCR master mix (2x), No 
AmpErase® UNG (Applied Biosystems), 1 μL of water, 0.4 μL of each primer (400 
nmol final concentration), 0.2 μL of the probe (200 nmol final concentration), 1 μL of 
1% bovine serum albumin (BSA, final concentration: 0.1%), and 2 μL of DNA (1:10 or 
1:100 dilution), and the PCR conditions were: 95°C for 20 s, and 40 cycles at 95°C for 5 
s, and 10 s at the optimized annealing temperature (Supplementary Table A3). SYBR-
based reaction mixtures (total 10 μL) contained 5 μL of SsoFastTM EvaGreen® supermix 
(Biorad Laboratories), 1.6 μL of water, 0.4 μL of each primer (final concentration: 400 
nmol), 1 μL of 1% BSA (final concentration: 0.1%), and 2 μL of DNA (1:10 or 1:100 
dilution). PCR conditions were 95°C for 2 min, and 40 cycles at 95°C 5 s and 10 s at the 
optimized annealing temperature. A melt curve analysis was performed for SYBR-based 
qPCR assays under the following conditions: 1 minute at 95°C, 1 minute at 55°C, and 80 
cycles of 0.5°C increments (10 s each). Amplicons were also visualized in an agarose gel 
(1%) to confirm the presence of one band of the expected molecular size. The qPCR data 
for Helicobacter, Lactobacillus, and Enterococcus spp. was normalized to the qPCR 
data for total bacteria and all samples were run in duplicate.  
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The abundance of total bacteria, Bifidobacterium, Lactobacillus, the Bacteroides-
Prevotella-Porphyromonas group, gamma-Proteobacteria (Class), Firmicutes (Phylum), 
Clostridium perfringens, as well as C. difficile and the C. difficile gene encoding toxin B, 
was evaluated in feces using published oligonucleotides (Supplementary Table A3). The 
abundance of Ruminococacceae (Family) and Faecalibacterium was also evaluated 
using family and genus-specific oligonucleotides (as assessed by 16S rRNA gene clone 
libraries) recently developed at our laboratory. SYBR-based qPCR assays were 
performed as described above (without BSA) at the optimized annealing temperature. A 
commercial real-time PCR thermal cycler (CFX96TM, Biorad Laboratories) was used for 
all qPCR assays. The DNA concentration of all fecal samples was adjusted to 5 ng μL-1. 
 
4.3.5 Fluorescence in situ hybridization (FISH) 
An average of 6 biopsies (range: 4-7 per organ evaluated) were obtained at each time 
point and from each dog, fixed in neutral-buffered 10% formalin, and embedded in 
paraffin. Histological sections (4 μm) were evaluated using FISH with oligonucleotide 
probes 5’-labeled with 6-FAM or Cy-5 targeting the 16S rRNA of total bacteria and 
Helicobacter (Supplementary Table A3) as described previously (Jergens et al., 2009). 
Gastric and duodenal bacteria were quantified every 3-5 microscopic fields throughout 
the mucosal perimeter of each biopsy, depending on the unique morphology of each 
specimen, using a Zeiss Stallion digital confocal microscope (Carl Zeiss Microimaging). 
To facilitate the quantification of bacteria at different levels of the glass slide, at least 
three consecutive pictures were taken sequentially throughout the vertical z axis (each 
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picture separated from one another by 0.5 μm) from each microscopic field. A C-
apochromat (63x water correction) objective lens was used for all FISH analyses.  
 
4.3.6 Statistical analysis 
To assess the diversity of the GI microbiota, the Shannon-Weaver diversity index was 
calculated. Alterations of microbial communities before, during, and after omeprazole 
administration, was investigated using principal component analysis (PCA) based on the 
phylogeny-based Unifrac distance metric (Lozupone & Knight, 2005). 
Parametric analyses. A general linear mixed model using the MIXED procedure 
of SAS 9.2 (SAS Institute, Inc.) was used to analyze the qPCR data with time, gender, 
and time*gender interaction as fixed effects. The inclusion of the interaction between 
time and gender is justified by the fact that all dogs were the same age, had a very 
similar body weight, and were subjected to the same diet and environmental conditions. 
In addition, time was also used in the REPEATED statement to model the repeated 
measures (before, during, and after omeprazole administration) and dog was included as 
a random effect. The log10 gastric Helicobacter FISH counts were analyzed using a 
general linear mixed model in SAS 9.2 and the same approach described for qPCR data. 
Post-hoc multiple comparisons were performed using the Tukey-Kramer method. All 
model residuals showed a distribution very close to normal, thus indicating valid models.  
Non-parametric analyzes. The Friedman’s test in Prism5 (GraphPad Software, 
CA) was used to compare the pyrosequencing data (percentage of sequences) for each 
bacterial group separately, gastric non-Helicobacter total FISH counts, and the indexes 
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of bacterial richness and diversity. Post-hoc multiple comparisons were performed using 
the Dunn’s post test. The NPAR1WAY procedure in SAS 9.2 was used to compare 
intragastric pH and duodenal bacterial FISH counts. A p value of less than 0.05 was 
considered to be statistically significant for all analyses. 
 
4.4 Results 
4.4.1 Side effects of omeprazole administration and intragastric pH 
All dogs remained clinically healthy throughout the study. Intragastric pH was 
significantly increased during omeprazole administration (median pH: 7.4, interquartile 
range: 7.2-7.9) when compared with intragastric pH on Days -30 (1.7, 1.5-1.9) and -15 
(1.8, 1.5-2.1) before administration, and Day 30 after omeprazole administration (1.5, 
1.4-6.8) (p=0.0037). The pH measurements did not correlate linearly or quadratically 
with gastric or duodenal bacterial FISH counts, pyrosequencing or qPCR data (results 
not shown).  
 
4.4.2 Pyrosequencing  
A total of 142,026 (stomach) and 133,449 (duodenum) sequences (~4,000 per sample 
evaluated) were analyzed. With the exception of the gastric microbiota of two male dogs 
at only one different time point each, the gastric and duodenal microbiota formed 
completely separated phylogenetic clusters (Supplementary Fig. A1), suggesting a 
distinctive microbiota in each of the evaluated sections of the gastrointestinal tract.  
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4.4.3 Pyrosequencing in gastric biopsies  
In the stomach, a median of 34 operational taxonomic units (OTUs >97% sequence 
identity) was detected per dog per time point. There was a significantly higher bacterial 
richness in the stomach during omeprazole administration but bacterial diversity was not 
significantly modified (Table 5). While we observed significant changes in specific 
bacterial groups in response to omeprazole administration (see below), the constructed 
dendrograms based on the Unifrac distance metric did not reveal an obvious clustering 
of animals according to treatment period (Supplementary Fig. A2). The great majority 
(>90% on average at baseline) of the obtained sequences from the stomach were 
classified as Proteobacteria, a phylum that decreased during omeprazole administration 
(p=0.0427, Supplementary Table A4). This effect was more evident on the genus 
Helicobacter (p=0.0336). The median percentage of Helicobacter spp. during 
omeprazole was 92%, the median percentage before and after omeprazole was >98%. 
This decrease in Helicobacter spp. during omeprazole administration was accompanied 
by an increase in other genera of the phyla Proteobacteria (especially Actinobacillus), 
Firmicutes (especially Streptococcus) and Fusobacteria (Supplementary Table A4).  
 
4.4.4 FISH in gastric biopsies  
Gastric Helicobacter and non-Helicobacter bacteria were counted throughout the 
mucosal side of a total of 155 gastric biopsies from a similar number of microscopic 
fields (Supplementary Table A5). There was a significant effect of omeprazole on the 
abundance of gastric Helicobacter (p<0.0001) and there was no difference in abundance 
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Table 5 Median (interquartile range) indexes of bacterial richness (OTUs 3%) and 
diversity (Shannon Weaver 3%) before, during and after omeprazole 
administration. Day -30 and Day -15 before omeprazole administration, Day 15 last 
day of omeprazole administration, and Day 30 after omeprazole administration 
(Day 30). P values were obtained by non-parametric Friedman’s tests 
 Stomach  
 Day -30 Day -15 Day  15 Day 30 p 
Shannon 1.1 (0.8/1.5) 1.5 (1.0/1.8) 1.2 (0.8/2.1) 0.6 (0.2/1.2) 0.0658 
OTU 32 (17/37)a 35 (20/46) 63 (36/82)a,b 22 (14/33)b 0.0021 
   
 Duodenum  
Shannon 2.8 (2.7/3.5) 2.9 (2.6/3.7) 2.8 (2.7/3.4) 2.7 (2.0/3.3) 0.8254 
OTU 156 
(114/176) 
206 (151/278) 145 
(123/181) 
156 (86/239) 0.2407 
a,b Same superscripts indicate statistically significant difference (p<0.05, Dunn’s 
multiple comparison).  
 
 
 
of gastric Helicobacter between the male and female dogs (p=0.3161). Also, there was a 
significant interaction between time and gender (p=0.0323), suggesting that the change 
in gastric Helicobacter organisms over time was different between the male and female 
dogs (Fig. 9). Also, in the stomach, non-Helicobacter bacteria were observed more 
frequently during omeprazole administration (median: 3, range: 0-20) than on Day -30 
(median: 0, range: 0-3) and Day -15 (median: 1, range: 0-6) before omeprazole 
administration, and 15 days after omeprazole administration on Day 30 (median: 0, 
range: 0-2) (p=0.0300).  
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4.4.5 Quantitative real-time PCR in gastric biopsies  
There was not a significant effect of omeprazole administration on gastric total bacteria 
(p=0.0687), there was no difference in bacterial abundance between the male and female 
dogs (p=0.7566), but there was a significant interaction between time and gender 
(p=0.0001) (Fig. 10). In the male dogs, there was a higher bacterial abundance during 
omeprazole administration on Day 15 (p=0.0093) and on Day 30 after discontinuation of 
omeprazole administration (p=0.0007) when compared with that on Day -30 before 
omeprazole administration (Fig. 10). There was no significant effect of omeprazole 
administration on total gastric bacteria in the female dogs and there was no significant 
effect of omeprazole administration on the abundance of gastric Helicobacter and 
Lactobacillus spp. (Fig. 10).  
 
4.4.6 Pyrosequencing in duodenal biopsies 
In the duodenum, a median of 163 OTUs (>97% sequence identity) was detected per dog 
per time point. Omeprazole administration was not associated with significant 
differences in the indexes of bacterial richness and/or diversity (Table 5). While we 
observed significant changes in specific bacterial groups in response to omeprazole 
administration (see below), the constructed dendrograms based on the Unifrac distance 
metric did not reveal an obvious clustering of animals according to treatment period 
(Supplementary Fig. A3). Bacterial representatives of at least seven different phyla were 
identified in the duodenum (Supplementary Table A6). The majority of the obtained 
sequences from the proximal duodenum were classified as Firmicutes, followed by 
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Proteobacteria and Bacteroidetes. On average, these three bacterial phyla represented 
more than 80% of all sequences at all time points. Omeprazole administration was 
associated with a higher abundance of Enterococcus (p=0.0137) and a lower abundance 
of Helicobacter (p=0.0287) and Porphyromonas (p=0.0316), but there was no 
statistically significant difference in all the rest of the analyzed bacterial groups analyzed 
(Supplementary Table A6). 
 
 
 
Fig. 9. Log10 Helicobacter FISH counts per microscopic field before, during and after 
omeprazole administration. Day 30 (D-30) and Day 15 (D-15) before omeprazole 
administration, the last day of omeprazole administration (D15), and 15 days after 
completion of omeprazole administration (D30) in the male (left) and the female (right) 
dogs. The error bars represent the mean and the standard error. Within each gender, there 
was a significant decrease in gastric Helicobacter during omeprazole administration at 
Day 15 (*, D15) when compared to all other time points (p<0.0001). 
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Fig. 10. Quantitative real-time PCR results for total gastric bacteria (a), gastric 
Helicobacter spp. (b), and gastric Lactobacillus spp. (c) before, during and after 
omeprazole administration. Day 30 (D -30) and Day 15 (D -15) before omeprazole 
administration, the last day of omeprazole administration (D 15), and 15 days after 
completion of omeprazole administration (D 30) in the male (left) and the female (right) 
dogs. Error bars represent the mean and the standard error. Horizontal brackets represent 
statistical significance (p<0.05).  
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  Interestingly, the effect of omeprazole administration on duodenal Lactobacillus 
spp. was noticed only in the male dogs (Supplementary Fig. A4). All four male dogs had 
an increase in the Class Bacilli (Phylum Firmicutes) during omeprazole administration 
(all had >70% during omeprazole administration while only two had more than 10% at 
either baseline evaluation) (Supplementary Fig. A4). This effect was also evident at the 
order Lactobacillales and the genera Enterococcus and Lactobacillus in three of the four 
male dogs. This consistent increase in Bacilli during omeprazole administration in the 
male dogs was associated with a lower abundance of other bacterial phyla (especially 
Proteobacteria and Bacteroidetes) during omeprazole administration. In the female dogs, 
no such consistent changes in the proportions of duodenal bacteria were observed.  
 
4.4.7 FISH in duodenal biopsies 
Duodenal total bacteria were counted in a total of 132 biopsies from a similar number of 
microscopic fields (Supplementary Table A5). While the median number of bacteria per 
microscopic field was zero for all time points (range: 0-3), non-parametric analyzes 
revealed higher numbers of bacteria during omeprazole administration (p=0.0033). The 
sum of all counted bacteria during omeprazole was 40 bacteria (male dogs only: 34), 
while the median sum of all other time points was 8 bacteria. All the observed bacteria 
were morphologically similar (i.e., rod-shaped, 2-3 μm long).  
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4.4.8 Quantitative real-time PCR in duodenal biopsies  
There was a significant effect of omeprazole administration on the abundance of total 
duodenal bacteria (p=0.0003), but there was no difference between genders and there 
was no significant interaction between omeprazole administration and gender. 
Regardless of gender, there was a higher bacterial abundance on Day 15 during 
omeprazole administration when compared to Day -15 before omeprazole administration 
(p=0.0295). Also, there was a higher bacterial abundance in the duodenum on Day 30 
after omeprazole administration when compared to that on Day -30 (p=0.0040) and Day 
-15 (p=0.0009) before omeprazole administration (Fig. 11). In contrast to the 
pyrosequencing results that showed a decrease of Helicobacter spp. in the duodenum 
during omeprazole administration, the genus Helicobacter was detected only at six 
isolated time points in the duodenum of five dogs (three male and two female dogs). 
Enterococcus spp. was detected only in two male dogs during omeprazole administration 
on Day 15. There was a significant effect of omeprazole on duodenal Lactobacillus 
(p<0.0001) with male dogs having a higher abundance of duodenal Lactobacillus when 
compared with female dogs (p=0.0168). Also, there was a significant interaction 
between omeprazole administration and gender (p<0.0001) (Fig. 11). The male dogs had 
a significantly higher abundance of Lactobacillus during omeprazole administration 
when compared to all time points before and after omeprazole administration (p<0.005 
for all multiple comparisons) (Fig. 11).  
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Fig. 11. Quantitative real-time PCR results for total duodenal bacteria (a) and 
Lactobacillus spp. (b) before, during and after omeprazole administration. Day 30 (D -
30) and Day 15 (D -15) before omeprazole administration, the last day of omeprazole 
administration (D 15), and 15 days after completion of omeprazole administration (D 
30). Horizontal brackets represent statistical significance (p<0.05). *Significantly 
different (p<0.05) than Day 15 before omeprazole administration (D -15), regardless of 
gender. † Significantly different (p<0.01) than Day 15 (D -15) and Day 30 (D -30) 
before omeprazole administration, regardless of gender. 
 
 
 
4.4.9 Fecal microbiota 
One fecal DNA sample (from one female dog, Day -15 before omeprazole 
administration) was not available and was treated as a missing value. All time points in 
all dogs were PCR negative for C. difficile and the C. difficile gene encoding toxin B. C. 
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perfringens was detected in all female dogs only on Day -30 before omeprazole 
administration. Regardless of gender, there was a significant increase in fecal 
Lactobacillus during omeprazole administration when compared with all other time 
points (p<0.05, Supplementary Fig. A5). This decrease in Lactobacillus was 
accompanied, in the male dogs, by a decrease of Faecalibacterium and the Bacteroides-
Prevotella-Porphyromonas group (Supplementary Fig. A5).  
 
4.5 Discussion 
PPIs and other suppressors of gastric acid secretion are used extensively in both human 
and veterinary patients with suspected disorders of the upper GI tract. Despite the 
widespread use of these compounds in dogs and the cumulative evidence suggesting an 
association between PPI use and GI infections in human patients, there are no studies to 
date that have evaluated the effect of PPIs or any other gastric acid suppressor on the 
composition of the canine GI microbiota. The results of this study suggest that orally 
administered omeprazole at a dose of 1.1 mg/kg twice a day for 15 days can alter the 
composition of the gastric, duodenal, and fecal bacterial microbiota of healthy dogs.  
In this study, omeprazole administration led to a decrease in gastric Helicobacter 
spp., an effect which was more evident on the quantitative FISH analysis. While a 
growing number of investigations suggest that PPIs can also lead to a decrease in the 
abundance of gastric Helicobacter pylori in humans, most studies have evaluated the 
effect of PPIs on this bacterium only in combination with other pharmaceuticals such as 
antibiotics (Graham & Fischbach, 2010, Luther et al., 2010, Wu et al., 2010). Also, the 
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histological density of H. pylori in the gastric body and antrum of humans was reduced 
after four weeks of omeprazole treatment, while it was increased in the fundus (Logan et 
al., 1995). Other studies have confirmed this phenomenon (Ishihara et al., 2001). This is 
important because in the current study we only collected biopsies from the gastric body 
and antrum, and therefore we cannot confirm an overall decrease in gastric Helicobacter 
in all regions of the stomach. Moreover, the quantitative real-time PCR assay used in 
this study did not confirm the decrease in gastric Helicobacter spp. abundance during 
omeprazole administration, an effect suggested by both pyrosequencing and FISH. It is 
possible that the qPCR assay used here does not detect all canine gastric species and 
strains of Helicobacter. For instance, while both the reverse primer and the oligo probe 
detect all Helicobacter spp. that have been isolated from the stomach in dogs (Neiger & 
Simpson, 2000), the forward primer may not detect H. bilis and Flexispira rappini. The 
latter may be especially relevant as it includes multiple Helicobacter taxa (Dewhirst et 
al., 2000). These observations raise the interesting question of whether the effect of 
omeprazole is different among different species and/or strains of gastric Helicobacter, a 
hypothesis that is indirectly supported by a recent study showing that the effect of 
pantoprazole (another PPI) on growth and morphology of bacteria was different among 
several strains of oral Lactobacillus spp. (Altman et al., 2008).  
The mechanism by which omeprazole leads to a decrease in gastric Helicobacter 
is unclear and controversial in the literature (Canani & Terrin, 2010). Omeprazole could 
have an indirect effect by means of raising intragastric pH, which in turn could allow 
other non-Helicobacter bacteria to thrive. Alternatively, omeprazole may act directly by 
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means of a direct bactericidal effect. For instance, it has been shown that omeprazole 
inhibits the growth of gram-positive and gram-negative bacteria in vitro, including H. 
pylori (Jonkers et al., 1996). More recent studies also support a direct effect of PPIs on 
H. pylori (Suzuki et al., 2003, Nakamura et al., 2007). This effect may be due to a direct 
effect on the proton-pumps of the bacteria, as these enzymes have been identified at least 
in H. pylori (Melchers et al., 1998) and Streptococcus pneumoniae (Hoskins et al., 
2001). Thus, it has been hypothesized that these enzymes of bacterial origin may serve 
as extrinsic sites of action for PPI therapy (Vesper et al., 2009). However, while much 
research has focused on H. pylori, dogs do not harbor this species in the stomach but 
other Helicobacter spp. such as H. felis and H. heilmannii (Neiger & Simpson, 2000, 
Shinozaki et al., 2002). To date, the effect of PPIs on other non H. pylori gastric 
Helicobacter spp. has not been investigated.  
The decrease in gastric Helicobacter abundance during omeprazole 
administration was accompanied by a higher abundance of other bacteria, especially 
Streptococcus, Lactobacillus, Fusobacterium, and Actinobacillus, whose abundances 
returned to baseline levels after discontinuation of omeprazole administration. It is likely 
that other, non-Helicobacter bacteria were able to thrive in the stomach during the 
temporary reduction in intragastric acidity. It is also possible that some of these bacteria 
possess a direct antagonist effect against Helicobacter spp., as suggested by a recent 
study of the effect of two strains of Lactobacillus on H. pylori (Cui et al., 2010). 
However, it is not clear whether the bacteria that were found more abundantly during 
omeprazole administration were native to the stomach or foreign, e.g., from the mouth 
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and esophagus. One study suggested that the human stomach could contain its own 
distinct microbial ecosystem (Bik et al., 2006), but the authors warned that this 
observation was based on a comparison of gastric, oral, and esophageal bacterial 
communities from different subjects with different clinical syndromes. 
 In the duodenum, omeprazole led to an increased abundance in Lactobacillus and 
Enterococcus in the male dogs, which likely caused the observed higher abundance of 
all bacteria suggested by FISH analysis.  In the past, an abnormal accumulation of 
bacteria in the small bowel of dogs was termed as small intestinal bacterial overgrowth 
(SIBO; Johnston, 1999), but the understanding of this phenomenon has undergone 
several advances (Hall, 2011), in part because of the complex microbial composition 
discovered in the canine small intestine (Mentula et al., 2005, Suchodolski et al., 2008, 
Xenoulis et al., 2008, Suchodolski et al., 2009, Suchodolski et al., 2010). In small 
animal veterinary medicine, small intestinal dysbiosis is a currently used term to define a 
clinical syndrome caused by an alteration, either qualitative, quantitative, or both, of one 
or more groups of the small intestinal microbiota. Although the observed changes in the 
composition of the duodenal microbiota during omeprazole administration may be 
considered abnormal (from its baseline composition), its clinical significance remains to 
be determined.   
 In addition to the changes in the stomach and duodenum, our results also suggest 
that omeprazole can alter the composition of the fecal microbiota. Similarly, one recent 
study showed that orally administered omeprazole can lead to changes in fecal microbial 
communities of mice in a dose-dependent manner (Kanno et al., 2009). However, unlike 
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the current study that showed a higher abundance of some fecal bacteria (e.g. 
Lactobacillus) accompanied by a lower abundance of other bacteria (e.g. 
Faecalibacterium and Bacteroides) during omeprazole administration, Kanno et al. 
showed that all groups of fecal bacteria (with the exception of Bifidobacterium) 
increased during omeprazole administration in mice (Kanno et al., 2009). Since 
omeprazole is metabolized by the hepatic cytochrome P450 system after absorption from 
the small intestine and about 80% of the metabolites are excreted in urine (Petersen, 
1995), it is unlikely that any omeprazole reach the large intestine, at least in its native 
form. Thus, our results and the results reported by Kanno et al. suggest that it is the 
increase in the bacterial load entering the intestinal tract that is responsible for the 
changes observed in the fecal microbiota. Another factor affecting the fecal microbiota 
during inhibition of gastric acid could be the change in the composition of dietary 
protein reaching the large intestine (Zentek et al., 2003), as gastric acid plays a key role 
in the initial stages of protein digestion. It seems likely that both mechanisms contribute 
to the changes observed in the fecal microbiota. The decrease in Faecalibacterium 
during omeprazole administration in the male dogs is especially interesting, as these 
bacteria possess anti-inflammatory properties (Sokol et al., 2008) and have been found 
to be depleted during episodes of colitis in humans (Sokol et al., 2009) . 
Finally, the interaction between the effect of omeprazole on the GI bacterial 
microbiota and gender suggested in this study may deserve scrutiny in future studies. 
Interestingly, Zhang et al. showed that higher endogenous progesterone concentrations 
in women could have a stimulatory effect on the P450 3A (CYP3A) activity (Zhang et 
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al., 2006), which plays an essential role in the metabolism of omeprazole in the liver 
(Andersson et al., 1993, Andersson et al., 1994). However, all the females in the current 
study did not have their first heat season until months after the last sample collection, 
and it has been shown that bitches have undetectable serum concentrations of 
progesterone during anestrous (Hase et al., 1999).  
In summary, this study suggests that orally administered omeprazole can alter the 
quantitative abundance of several bacterial communities throughout the GI tract of 
healthy dogs. Particularly, in this study omeprazole administration was associated with a 
decrease in Helicobacter spp. and an increase of other bacteria in the stomach. Also, 
omeprazole administration was associated with higher numbers of total bacteria and an 
increase in Lactobacillus in the duodenum of the male dogs. Lastly, omeprazole led to 
an increase in fecal Lactobacillus, which was accompanied by a decrease in 
Faecalibacterium and the Bacteroides-Prevotella-Porphyromonas group in the male 
dogs. However, omeprazole administration was not associated with major qualitative 
changes in the phylogenetic composition of the stomach and the duodenum, as evaluated 
by Unifrac analysis of pyrosequencing results. Further studies are warranted to 
investigate the clinical significance of these findings. 
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5. CHARACTERIZATION OF THE FECAL MICROBIOTA IN HEALTHY 
DOGS 
 
5.1  Overview  
This study evaluated the abundance of the Clostridium coccoides- Eubacterium rectale 
(Erec) group using fluorescence in situ hybridization in feces of healthy dogs (n=6) at 
two time points (15 days apart). Dogs harbored a median of 1.8x1010 total bacteria 
(range: 1.1x1010 to 2.9x1010, as assessed by DAPI staining) and 3.7x109 organisms 
belonging to the Erec group (range: 1.2x109 to 6.7x109) per gram of wet feces. The Erec 
group comprised a median of 22% of total bacteria (range: 10-42%). The difference in 
median Erec/DAPI ratios between the two evaluated time points ranged from 1 to 21%. 
The intra-individual coefficient of variation (%CV) between the two evaluated time 
points ranged from 27 to 41% for total bacteria (as assessed by DAPI staining), 30 to 
53% for Erec, and 28 to 81% for the ratio of Erec/total bacteria. However, when 
transformed to the log10 scale, the highest difference in median abundance of bacteria 
between the two evaluated time points was only 0.23 for total bacteria and 0.45 for Erec. 
The median inter-individual %CV was 43% for total bacteria, 48% for Erec, and 53% 
for the Erec/total bacteria ratio. This study shows that the Erec group is abundant (22% 
of all fecal microbiota) and varies little (<0.5 in the log10 scale) within a period of 15 
days in the feces of healthy dogs. 
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5.2 Introduction 
Fluorescence in situ hybridization (FISH) is a culture-independent molecular technique 
that allows for the analysis of the composition and dynamics of the intestinal microbiota 
(Amann & Fuchs, 2008). The principles of the FISH technique have been described 
elsewhere (Moter & Gobel, 2000). 
The oligonucleotide FISH probe Erec482 was designed to detect the Clostridium 
coccoides-Eubacterium rectale (Erec) group (Franks et al., 1998), which at that time 
included most of the Clostridia and Eubacteria belonging to Clostridium clusters XIVa 
and XIVb. The Erec group (as evaluated by FISH using the Erec482 probe) is one of the 
most predominant bacterial groups in human feces. For example, several studies have 
shown that bacteria belonging to the Erec group comprises from 10 to 29% of all fecal 
bacteria (Franks et al., 1998, Tannock et al., 2000, Marteau et al., 2001, Matsuki et al., 
2004, Mueller et al., 2006, Swidsinski et al., 2008). Aside their importance as one of the 
most predominant bacterial groups in feces (Sekelja et al., 2011), some bacteria 
belonging to the Erec group have been linked to some forms of inflammatory bowel 
disease in humans (Sokol et al., 2006).  
Despite the relevance of the Erec group as a major component of the fecal 
microbiota in humans, only one study has used FISH to evaluate the in vivo abundance 
of bacteria of the Erec group in feces of dogs (Jia et al., 2010). Therefore, the objective 
of this study was to evaluate the abundance and short-term temporal variability of 
bacteria of the Erec group using FISH.  
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5.3 Materials and methods 
Naturally passed fecal samples from a total of six dogs (median age: 4 years, range: 9 
months to 10 years) were used in this study. All subjects were privately owned pets with 
no clinical signs of gastrointestinal disease, such as diarrhea or vomiting, that consumed 
their routine diet during the study period. Two separate fecal samples (15 days apart) 
were collected and stored at 4°C for less than 24 hours before processing.  
 
5.3.1 Fluorescence in situ hybridization 
Paraffin embedded fecal blocks (PEFB) were prepared for FISH analysis. Briefly, 100 
mg (wet weight) of each fecal sample was mixed with 500 μl of paraformaldehyde in a 
microcentrifuge tube and incubated for 12 h at 4˚C. The tubes were then centrifuged, the 
supernatant transferred into another tube, and the pellet washed with phosphate buffered 
saline (pH 7.2). After centrifugation, the supernatant from these two previous steps was 
mixed and partially dehydrated using a VacufugeTM (Eppendorf) at 45°C for 2 hours. 
Both the washed fecal pellet and the dehydrated supernatant were then mixed with 1 ml 
of HistoGelTM (LabStorage Systems Inc.) using a FastPrep®-24 (MP Biomedicals). The 
agar containing the fecal specimen was poured into a histology cassette (standard, 
25x20x5 mm, Tissue-Tek®) and allowed to solidify for 5 minutes at room temperature. 
At this stage (i.e., before paraffinization) the fecal blocks can be stored at 4°C for up to 
two weeks, but longer storage might favor fungal growth.  Also, the blocks should not be 
stored in 70% EtOH before paraffinization (as usually done with tissue samples) because 
this could have a dilution effect on the fecal specimen with potential loss of bacterial 
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organisms. After paraffinization, the fecal blocks are rectangular cubes of ~25x20x3 mm 
(Fig. 12). 
 
 
 
 
Fig. 12. Paraffin embedded fecal blocks. 
 
 
 
FISH was performed as described previously (Thiel & Blaut, 2005), with 
modifications. Two serial paraffin sections from each paraffin embedded fecal block 
were cut (5 μm) and placed onto coated slides (ProbeOn Plus, Fisher Scientific). The 
oligonucleotide probe GCTTCTTAGTCARGTACCG (Erec482, targeting the 16S rRNA 
of the Clostridium coccoides- Eubacterium rectale (Erec) group as described by Franks 
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et al., 1998) was labeled at the 5’-end with Cy-5 (Integrated DNA technologies), 
reconstituted with sterile water, and diluted to a concentration of 30 ng/μL with a 
hybridization buffer (20 mM Tris, 0.9 M NaCl, 0.1% SDS, pH 7.2). Paraffin-embedded 
biopsy specimens were deparaffinized by passage through xylene (3 x 10 min), 100% 
ethanol (2 x 5 min), 95% ethanol (5 min), and 70% ethanol (5 min). After the slides were 
air-dried, the sections were allowed to hybridize with 10 μL of the probe (30 ng/μL) in a 
hybridization chamber for 4 hours at 50°C. After this, slides were rinsed with water and 
washed with an appropriate wash buffer (hybridization buffer without SDS) for 30 
minutes at 52°C. The slides were rinsed with sterile water and mounted with ProLong® 
Gold Antifade reagent Gold (Invitrogen) containing 4,6-diamidino-2-phenylindole 
(DAPI). The number of bacteria per gram of wet feces was calculated using the 
following formula: 
Bacterial cells g-1 wet feces = (number of bacteria per microscopic field) X (33,859) X 
(600) X (10),  
where: 33,859 is the number of microscopic fields (area of one microscopic field: 14,767 
μm2) in one paraffin section (area of one paraffin section: 500 mm2); 600 is the number 
of 5 μm paraffin sections per paraffin block (height of one paraffin block: 3 mm); and 10 
is the factor to multiply by to obtain the number of bacteria per gram of wet feces (100 
mg of feces were used to make each paraffin block). 
To our knowledge, the use of ImageJ (image analysis software, NIH, USA) to 
quantify fluorescently-labeled fecal bacteria has not been described. Therefore, it was 
important to first determine the most suitable method to quantify fecal bacteria. For this 
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purpose, four serial paraffin sections (5 μm) from one canine PEFB were cut, placed 
onto a glass slide, and coated. FISH was performed as described above.  
 
5.4 Results 
To first identify the most suitable method to quantify the bacteria, a total of 60 
microscopic fields (4 paraffin sections, 15 fields each) were analyzed. The Erec group 
was quantified in all of the 60 microscopic fields using three different approaches. First, 
the operator counted the bacteria manually using the cell counter feature in ImageJ 
(version 1.44p). Second, the bacteria were quantified by adjusting the threshold signal to 
match exactly the number of bacteria counted by the operator (JG) in one random 
microscopic field. After the threshold was adjusted, the analyze particles feature in 
ImageJ was utilized to automatically count all bacteria in each set of 15 microscopic 
fields. Thirdly, the bacteria were quantified by adjusting the threshold signal until all 
bacteria were labeled and then by decreasing the threshold signal until the numbers 
matched the manual quantification of the first paraffin section. After the threshold was 
adjusted, the analyze particles feature in ImageJ was utilized to automatically count all 
bacteria in each set of 15 microscopic fields. Based on the obtained results, the modified 
automatic approach (threshold adjusted to all labeled bacteria minus 40 fluorescent 
threshold units) was used to quantify bacteria belonging to the Erec group.  After a 
similar analysis of images for the Erec group (results not shown), we decided to also use 
a modified automatic approach (threshold adjusted to all labeled bacteria minus 45 
fluorescent threshold units) to quantify all bacteria (DAPI staining). 
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5.4.1 Quantification of bacteria 
To evaluate the abundance and variation of the predominant fecal microbiota, a total of 
240 microscopic fields were analyzed (6 dogs, two time points, two paraffin sections 
each, 10 microscopic fields per section). Dogs harbored a median of 1.8x1010 total 
bacteria per gram wet feces (range: 1.1x1010 to 2.9x1010), as estimated by DAPI staining, 
and 3.7x109 bacteria of the Erec group per gram wet feces (range: 1.2x109 to 6.7x109) 
(Fig. 13). The Erec group comprised an overall median of 22% of all fecal bacteria 
(range: 10-42%) (Fig. 14). The difference in the median Erec/DAPI ratios between the 
two evaluated time points ranged from 1 to 21% (Fig. 14). The intra-individual %CV 
ranged from 27 to 41% for total bacteria (as estimated by DAPI), 30 to 53% for Erec 
bacteria, and 28 to 81% for the Erec/DAPI ratio (Figs. 13 and 14). When transformed to 
the log10 scale, the highest difference in median abundance of bacteria between the two 
evaluated time points was 0.45 for Erec bacteria and 0.23 for total bacteria (DAPI) (Fig. 
15). The median inter-individual %CV was 43% for total bacteria, 48% for Erec 
bacteria, and 53% for the Erec/DAPI ratio (Figs. 13 and 14). The Erec FISH counts 
correlated positively with the total bacteria as estimated by DAPI staining (R2=0.10, 
p<0.0001) (Fig. 16). The Erec counts also correlated positively with the Erec/DAPI 
ratios (R2=0.32, p<0.0001) (Fig. 17). In contrast, total bacterial FISH counts correlated 
negatively with the Erec/DAPI ratios (R2=0.23, p<0.0001) (Fig. 17). 
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Fig. 13. Total fecal bacteria as estimated by DAPI staining (A) and bacteria of the Erec 
group (B) per wet gram of feces. 
 
 
 
 
 
Fig. 14. Percentage of Erec FISH counts to total fecal bacteria (as estimated by DAPI 
staining). 
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Fig. 15. Log10 total fecal bacteria as estimated by DAPI staining (A) and log10 bacteria 
of the Erec group (B) per gram of wet feces. 
 
 
 
 
 
 
Fig. 16. Linear relationship (R2: 0.10) between the Erec FISH counts (x axis) and total 
fecal bacteria (as estimated by DAPI staining, y axis). 
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Fig. 17. Linear relationship between total FISH bacterial counts (as estimated by DAPI 
staining) and the Erec/DAPI ratios (A), and between Erec FISH counts and the 
Erec/DAPI ratios (B). A: R2: 0.23; B: R2: 0.32. 
 
 
 
5.5 Discussion 
The FISH probe Erec482 was designed to detect the Clostridium coccoides-Eubacterium 
rectale (Erec) group (Franks et al., 1998). Because of the high abundance of bacteria of 
the Erec group in human feces and its potential involvement in the pathogenesis of 
inflammatory bowel disease, the goal of this study was to investigate the abundance of 
bacteria of the Erec group using FISH in feces of healthy dogs at two time points (15 
days apart).   
The probe Erec482 has been used to evaluate the abundance of bacteria of the 
Erec group in multiple human studies (Marteau et al., 2001, Matsuki et al., 2004, Sokol 
et al., 2006). Also, one recent study showed that dogs harbor on average 9.2 to 9.6 log10 
cells per gram of wet feces (~10% of total bacteria as estimated by DAPI staining) of the 
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Erec group (Jia et al., 2010). Similarly, the current study showed an overall median of 
3.7x109 (9.6 log10) cells per gram of wet feces of bacteria of the Erec group (overall 
median: 22 % of all fecal bacteria as estimated by DAPI staining). The difference in the 
proportions of the Erec group between the study by Jia et al. (10%) and the current study 
(22%) is likely due to inter-individual differences in total fecal bacterial counts as well 
as to variations in the method of quantification of bacteria (manual versus automatic 
quantification in the current study).  
The probe Erec482 was designed to detect bacteria of the Erec group (Franks et 
al., 1998), which at that time included several species of the genera Butyrivibrio, 
Clostridium, Eubacterium, Roseburia, and Ruminococcus. However, some of these 
bacterial groups have recently been reclassified (Wiegel et al., 2006, Liu et al., 2008). 
Based on the current Ribosomal Database Project (RDP), Erec482 matches 16S rRNA 
gene sequences mostly within the phylum Firmicutes (>99% of all the 16S rRNA gene 
sequences detected by the Erec482 probe fall within this phylum), especially within the 
genus Blautia (89% of all sequences fall within the genus) and the family 
Lachnospiracea (67% of all sequences fall within the family, especially the genera 
Butyrivibrio, Coprococcus, Roseburia, Dorea, Anaerostipes, and Pseudobutyrivibrio). In 
contrast, Erec482 does not match many sequences within the families Ruminococcaceae 
or Eubacteriaceae (<0.1% of all sequences within the families). Studies are needed to 
evaluate the true specificity of Erec482 for fecal bacteria in dogs. 
In summary, this study shows that the Clostridium coccoides-Eubacterium 
rectale (Erec) group (as estimated by FISH using the Erec482 probe) comprises about 
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22% of all fecal bacteria in healthy dogs. Despite some variation in the actual fecal 
bacterial numbers between the two sampled time points, when transformed to the log10 
scale, the highest difference in median abundance of bacteria between the two time 
points evaluated was 0.45 for Erec bacteria and 0.23 for all bacteria. More studies are 
needed and ongoing to evaluate the abundance of more bacterial groups with potential 
clinical relevance. 
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6. CONCLUSIONS 
 
The GI microbiota is the collection of all microorganisms inhabiting the GI tract and has 
been characterized using both culture and molecular methods. While culture methods 
allow for detailed metabolic and biochemical studies, these methods are not suitable for 
an in-depth characterization of the GI microbiota because the growth requirements for 
most GI microorganisms are unknown or poorly understood. The study and 
understanding of the GI microbiota is important because GI microorganisms serve as a 
defense mechanism against pathogens, harvest energy from nutrients that were not 
assimilated by the host, and provide substances that support the growth of intestinal 
epithelial cells.  
 Probiotics are defined as live microorganisms that when consumed in adequate 
quantities confer a health benefit to the host. While probiotics are administered 
increasingly frequent to cats and dogs in an effort to increase the number of beneficial 
bacteria in the intestinal tract, most studies have focused on the effect of probiotics on 
specific bacterial groups. Therefore, very little is known about the effect of probiotics on 
the overall composition of the GI microbiota. The results of this study suggest that the 
ingestion of probiotics leads to an increase abundance of the administered bacterial 
groups in feces. However, this increase does not lead to significant changes in the 
overall composition of the fecal microbiota, as suggested by pyrosequencing. It is 
therefore likely that probiotics may exert their effect by inducing the production of 
beneficial substances without modifying the overall composition of the intestinal 
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microbiota. More studies are needed to evaluate the functional (metabolic) effect of 
probiotics on the intestinal microbiota.  
 This study also demonstrated a highly individualized response to probiotic 
colonization. This would suggest that baseline characteristics of each individual animal 
could affect the extent of intestinal colonization by the ingested probiotic. Specifically, 
quantitative real-time PCR analyses showed big differences in the abundance of 
probiotic bacteria over time (during and after the administration of the probiotic 
formulation) among different subjects. Therefore, we investigated the effect of age, 
baseline abundance of probiotic bacteria, and body weight as potential predictors of fecal 
colonization by the ingested probiotics (defined as an increase in the abundance of the 
probiotic groups in feces, as assessed by qPCR). In dogs, neither age nor baseline fecal 
abundance of probiotic bacteria were significant predictors of fecal colonization. 
Interestingly, body weight was also not a significant predictor of fecal colonization in 
the dogs, nor was body weight linearly related with the abundance of any of the 
evaluated fecal bacterial groups. This observation could reflect a lack of an association 
between the body weight of the dogs and the number of bacteria excreted in feces. In 
contrast, cats that had a lower fecal abundance of probiotic bacteria before consuming 
the probiotic formulation had a higher abundance of the probiotic bacteria during the 
consumption of the probiotic when compared with the period after discontinuation of 
probiotic administration. In addition, we found a significant interaction between the age 
of the cats and period of probiotic administration, suggesting that the age in cats could 
also be related to the extent of fecal colonization by the probiotics ingested. As in dogs, 
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body weight was not a significant predictor of fecal colonization in cats, although this 
finding was not surprising because all the cats enrolled had very similar body weights.   
 The secretion of gastric acid is one of the most proximal mechanisms to avoid 
the introduction of potentially harmful infectious agents into the intestinal tract. 
Suppressors of gastric acid secretion are used extensively in both human and veterinary 
medicine to treat gastric acid-related disorders of the upper GI tract. The consumption of 
these therapeutic agents has been linked to GI disorders, such as an increased risk of 
diarrhea and a higher prevalence of intestinal infections, a phenomenon potentially 
associated with intestinal microbial dysbiosis. However, the effect of inhibitors of gastric 
acid secretion on the GI microbiota of dogs has not been investigated. These results 
showed that the proton-pump inhibitor omeprazole led to a decrease in gastric 
Helicobacter spp. organisms. However, in this study we only obtained samples from the 
gastric body/antrum and therefore we could not confirm an overall decrease in gastric 
Helicobacter spp. organisms. This is important because studies in humans suggest that 
one species of Helicobacter (H. pylori) can relocate from the antrum to the fundus in 
response to omeprazole administration. In the duodenum, omeprazole administration led 
to an increase in Lactobacillus and Enteroccous spp. in male dogs only. Interestingly, in 
this study we also found evidence that omeprazole could alter the abundance of different 
bacterial groups in the feces, which is likely due to an increased load of bacteria in the 
small intestine or to a change on the composition of dietary protein, as gastric acid plays 
an important role in the digestion of proteins. In spite of the observed increased 
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abundance of several GI bacterial groups, omeprazole administration was not associated 
with major changes in predominant bacterial phyla in the stomach or the duodenum. 
 The studies using 454-pyrosequencing revealed that the GI tract of cats and dogs 
contain a heterogeneous group of microorganisms, as members of at least five different 
phyla were identified in different segments of the GI tract. However, the exact 
quantification of the GI microorganisms remains an important task to fully characterize 
the composition of the GI microbiota. These results showed that about 22% of all fecal 
microbiota in healthy dogs are composed by one group of phylogenetically related 
bacteria within the phylum Firmicutes, the Clostridium coccoides-Eubacterium rectale 
group (Clostridium cluster XIVa and XIVb) as described by Franks et al. (1998). The 
results also showed that the abundance of this bacterial group in feces of healthy dogs 
varies little (less than 0.5 on a log10 scale) within a period of 15 days. The knowledge of 
this variation may help future studies to define a biologically significant effect of 
probiotics and other agents on the abundance of the intestinal microbiota. 
  In summary, the GI tract of cats and dogs as well as other mammals is colonized 
by different types of microorganisms. Dietary and therapeutic interventions are 
associated with specific changes in the abundance and/or composition of certain 
bacterial groups in the GI tract of healthy cats and dogs, as assessed by culture-
independent molecular techniques targeting the 16S rRNA and the 16S rRNA gene. 
However, the effect of these agents on the GI microbiome may also include changes at 
the metabolic (functional) level. Therefore, future studies should aim to complement a 
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phylogenetic characterization of the intestinal microbiota with functional assays to 
evaluate the effect of these and other factors on GI and overall health.  
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APPENDIX A 
Supplementary Table A1. Medians and interquartile ranges of bacterial tags 
(percentages of all sequences) obtained by pyrosequencing before synbiotic 
administration at baseline (BL), after five days of administration of the synbiotic 
formulation (Day 5), and two days after discontinuation of administration of the 
synbiotic formulation (Day 23) in the cats enrolled. P values are either for a comparison 
of means (ANOVA) or ranks (non-parametric Friedman’s test)a.  
 
Phylum BL DAY 5 DAY 23 P 
Firmicutes 95.1 (91.1/97.0) 94.5 (92.2/98.7) 97.2 (95.9/98.3) 0.3679 
Actinobacteria 4.0 (2.5/8.6) 3.1 (1.1/7.1) 1.6 (1.0/2.6) 0.0458† 
Bacteroidetes 0.1 (0.0/0.8) 0.1 (0.0/1.0) 0.5 (0.3/0.9) 0.2028 
Proteobacteria 0.0 (0.0/0.2) 0.0 (0.0/0.2) 0.0 (0.0/0.2) 1.0000 
Fusobacteria 0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.0 (0.0/0.0) 0.6969 
Class     
Clostridia 66.0 (51.1/87.7) 66.7 (46.9/87.1) 78.7 (38.8/88.0) 0.7165 
Erysipelotrichi 11.8 (4.4/18.8) 9.3 (2.4/16.0) 14.2 (3.2/25.3) 0.1738 
Actinobacteria  4.0 (2.5/8.6) 3.1 (1.1/7.1) 1.6 (1.0/2.6) 0.0458† 
Bacilli 3.4 (0.6/20.9) 8.2 (2.8/43.0) 0.6 (0.1/10.0) 0.0755 
Bacteroidetes  0.1 (0.0/0.8) 0.1 (0.0/1.0) 0.5 (0.3/0.9) 0.2028 
Fusobacteria  0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.0 (0.0/0.0) 0.6969 
Order     
Clostridiales 66.0 (51.1/87.7) 66.7 (46.9/87.1) 78.7 (38.8/88.0) 0.7165 
Erysipelotrichales 11.8 (4.4/18.8)  9.3 (2.4/16.0) 14.2 (3.2/25.3) 0.1738 
Coriobacteriales 4.0 (2.5/8.6) 3.1 (1.1/7.1) 1.6 (1.0/2.6) 0.0458† 
Lactobacillales 3.4 (0.6/20.8) 8.2 (2.8/43.0) 0.4 (0.1/10.0) 0.1245 
Bacteroidales 0.1 (0.0/0.8) 0.1 (0.0/1.0) 0.5 (0.3/0.9) 0.2028 
Fusobacteriales 0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.0 (0.0/0.0) 0.6969 
Family     
Clostridiaceae 23.2 (8.6/26.4) 19.0 (8.0/26.4) 24.2 (16.6/39.7) 0.1834 
Lachnospiraceae 21.5 (18.5/33.0) 21.9 (10.0/29.2) 17.0 (6.7/26.6) 0.3385 
Ruminococcaceae 18.1 (10.1/21.5) 17.9 (8.9/36.7) 13.6 (9.4/21.5) 0.7788 
Erysipelotrichaceae 11.8 (4.4/18.8) 9.3 (2.4/16.0) 14.2 (3.2/25.3) 0.3259 
Coriobacteriaceae 4.0 (2.5/8.6) 3.1 (1.1/7.1) 1.6 (1.0/2.6) 0.0458† 
Eubacteriaceae 1.2 (0.4/2.4) 0.5 (0.2/1.9) 1.1 (0.4/2.5) 0.4724 
Enterococcaceae 0.5 (0.0/5.8) 5.4 (1.1/8.2) 0.1 (0.0/0.6) 0.1214 
Veillonellaceae 0.1 (0.0/1.2) 0.1 (0.0/0.5) 0.2 (0.0/0.3) 0.9048 
Bacteroidaceae 0.0 (0.0/0.1) 0.0 (0.0/0.4) 0.1 (0.0/0.4) 0.1822 
Prevotellaceae 0.0 (0.0/0.2) 0.0 (0.0/0.5) 0.3 (0.1/0.5) 0.0793 
Lactobacillaceae 0.0 (0.0/1.6) 0.4 (0.2/7.0) 0.0 (0.0/0.9) 0.0390† 
Fusobacteriaceae 0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.0 (0.0/0.0) 0.6969 
Streptococcaceae 0.0 (0.0/0.2) 0.0 (0.0/0.1) 0.1 (0.0/0.1) 0.5292 
Genusb     
Clostridium 22.5 (8.6/25.6) 18.9 (7.7/26.4) 24.1 (16.5/29.5) 0.2388 
Roseburia 16.1 (11.1/27.0) 14.5 (5.9/18.4) 8.1 (5.0/21.9) 0.1464 
Ruminococcus 11.7 (6.5/19.2) 11.4 (5.2/27.7) 9.4 (5.0/14.2) 0.2238 
Turicibacter 5.5 (3.1/10.2) 5.8 (0.4/8.3) 9.4 (2.1/11.5) 0.1738 
Dorea 5.1 (3.6/8.4) 4.0 (2.3/9.8) 4.2 (1.1/7.5) 0.3385 
Catenibacterium 3.4 (0.8/7.7) 1.3 (0.1/6.6) 0.9 (0.2/9.6) 0.4412 
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Collinsella 2.7 (2.0/7.3) 1.7 (0.8/3.8)* 1.2 (0.8/2.1)* 0.0062 
Sporobacter 1.8 (1.0/5.6) 2.7 (0.8/5.0) 2.4 (0.8/5.6) 0.7165 
Eubacterium 1.2 (0.4/2.4) 0.5 (0.2/1.9) 1.1 (0.4/2.5) 0.4724 
Enterococcus 0.5 (0.0/5.8) 5.4 (1.1/8.2) 0.1 (0.0/0.6) 0.1214 
Faecalibacterium 0.4 (0.2/0.9) 0.3 (0.0/1.9) 0.8 (0.2/1.3) 0.7584 
Peptococcus 0.2 (0.1/0.6) 0.1 (0.1/0.3) 0.3 (0.0/0.5) 0.7165 
Acetanaerobacterium 0.1 (0.0/0.3) 0.0 (0.0/0.1) 0.2 (0.1/0.5) 0.1637 
Slackia 0.1 (0.1/0.2) 0.1 (0.1/0.3) 0.2 (0.0/0.3) 0.9200 
Coprococcus 0.1 (0.0/0.2) 0.1 (0.0/0.2) 0.0 (0.0/0.1) 0.2053 
Olsenella 0.1 (0.0/2.1) 0.1 (0.0/0.8) 0.0 (0.0/0.2) 0.0164† 
Bulleidia 0.1 (0.0/0.8) 0.0 (0.0/1.1) 0.0 (0.0/0.8) 0.1801 
Anaerovorax 0.1 (0.0/0.2) 0.0 (0.0/0.3) 0.1 (0.0/0.3) 0.8187 
Lactobacillus 0.0 (0.0/1.6) 0.4 (0.2/7.0) 0.0 (0.0/0.9) 0.0390† 
Eggerthella 0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.8588 
Anaerotruncus 0.0 (0.0/0.0) 0.0 (0.0/0.1) 0.1 (0.0/0.1) 0.0558 
Anaerostipes 0.0 (0.0/0.4) 0.0 (/0.0/0.2) 0.0 (0.0/0.1) 0.1496 
Dialister 0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.1 (0.0/0.1) 0.8276 
Syntrophococcus 0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.0764 
Mogibacterium 0.0 (0.00.4) 0.0 (0.0/0.4) 0.0 (0.0/0.1) 0.0970 
Desulfotomaculum 0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.1 (0.0/0.1) 0.6291 
Prevotella 0.0 (0.0/0.2) 0.0 (0.0/0.5) 0.3 (0.1/0.5) 0.0793 
Streptococcus 0.0 (0.0/0.2) 0.0 (0.0/0.1) 0.0 (0.0/0.1) 0.4966 
Bacteroides 0.0 (0.0/0.1) 0.0 (0.0/0.4) 0.1 (0.0/0.4) 0.1822 
 
 
A total of 75,350 pyrosequencing tags were evaluated at baseline (BL), 60,355 on day 5 
of administering the synbiotic (Day 5), and 51,691 two days after discontinuation of 
administration of the synbiotic formulation (Day 23).  
a P values in this table are not adjusted for falsely rejected null hypotheses. After 
adjustment, none of these P values were found to be lower than the Benjamin-Hochberg 
critical values, suggesting that the significant P values (P<0.05) are rejecting the null 
hypothesis that all three time points are equal when this is true (Type I error). 
b Clostridium, Ruminococcus, Collinsella, and Sporobacter were the only bacterial 
genera that were detected at all time points in all of the subjects. The rest of the genera in 
this table were found in samples from at least 2 time points in at least half of the 
subjects. The remaining 58 genera found were only detected sporadically across subjects 
and therefore are not included in this table. 
* Significantly lower than baseline (P<0.05).  
† Multiple comparisons across the three time points did not reach statistical significance. 
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Supplementary Table A2. Median and interquartile ranges of bacterial tags 
(percentages of all sequences) obtained by pyrosequencing before synbiotic 
administration at baseline (BL), after five days of administration of the synbiotic 
formulation (Day 5), and two days after discontinuation of administration of the 
synbiotic formulation (Day 23) in the enrolled dogs. P values are either for a comparison 
of means (ANOVA) or ranks (non-parametric Friedman’s test)a. 
 
 
Phylum BL DAY 5 DAY 23 P 
Firmicutes 96.9 (94.6/98.5) 96.3 (89.3/97.9) 97.5 (86.6/99.1) 0.9200 
Actinobacteria 1.6 (0.7/2.7) 2.0 (1.1/5.3) 0.9 (0.6/2.1) 0.1482 
Bacteroidetes 0.1 (0.0/1.0) 1.1 (0.0/4.4) 0.3 (0.0/0.7) 0.3872 
Proteobacteria 0.1 (0.0/0.2) 0.1 (0.0/0.3) 0.1 (0.1/0.3) 0.5441 
Fusobacteria 0.1 (0.0/0.5)c 0.8 (0.0/1.9)c 0.2 (0.1/1.1)d 0.0128 
Class     
Clostridia 69.9 (42.9/82.6) 80.7 (66.8/90.9) 75.0 (67.6/92.0) 0.0755 
Erysipelotrichi 6.7 (0.8/27.7) 6.7 (2.5/13.8)  7.5 (1.4/11.9) 0.4657 
Bacilli 1.5 (0.1/42.4) 0.2 (0.0/1.4) 1.2 (0.0/12.7) 0.7165 
Actinobacteria  1.6 (0.7/2.7) 2.0 (1.1/5.3) 0.9 (0.6/2.1) 0.1482 
Bacteroidetes  0.1 (0.0/1.0) 1.1 (0.0/4.4) 0.3 (0.0/0.7) 0.3872 
Fusobacteria  0.1 (0.0/0.5)c 0.8 (0.0/1.9)c 0.2 (0.1/1.1)d 0.0128 
Order     
Clostridiales 69.9 (42.9/82.6) 80.7 (66.8/90.9) 75.0 (67.6/92.0) 0.0755 
Erysipelotrichales 6.7 (0.8/27.7) 6.7 (2.5/13.8)  7.5 (1.4/11.9) 0.4657 
Lactobacillales 1.5 (0.0/42.4) 0.2 (0.0/1.4) 1.2 (0.0/12.7) 0.7165 
Coriobacteriales 1.6 (0.7/2.7) 2.0 (1.1/4.3) 0.9 (0.6/2.1) 0.1482 
Bacteroidales 0.1 (0.0/1.0) 1.1 (0.0/4.4) 0.3 (0.0/0.7) 0.3872 
Fusobacteriales 0.1 (0.0/0.5)c 0.8 (0.0/1.9)c 0.2 (0.1/1.1)d 0.0128 
Family     
Clostridiaceae 22.8 (15.3/43.7) 34.9 (16.8/39.4) 26.8 (17.1/44.3) 0.7624 
Ruminococcaceae 19.1 (13.4/27.8) 22.6 (16.5/31.3) 20.5 (6.8/32.7) 0.3892 
Lachnospiraceae 13.0 (9.2/20.9) 13.2 (7.4/24.7) 12.0 (8.2/17.7) 0.6976 
Erysipelotrichaceae 6.7 (0.8/27.7) 6.7 (2.5/13.8) 7.5 (1.4/11.9) 0.4657 
Bacteroidaceae 0.0 (0.0/0.8) 0.1 (0.0/1.1) 0.1 (0.0/0.3) 0.6065 
Prevotellaceae 0.0 (0.0/0.4) 0.4 (0.0/3.2) 0.1 (0.0/0.5) 0.1522 
Coriobacteriaceae 1.6 (0.7/2.7) 2.0 (1.1/4.3) 0.9 (0.6/2.1) 0.1482 
Lactobacillaceae 0.0 (0.0/0.3) 0.0 (0.0/0.1) 0.0 (0.0/0.0) 0.5308 
Enterococcaceae 0.0 (0.0/0.1) 0.2 (0.0/0.5) 0.0 (0.0/2.7) 0.2319 
Eubacteriaceae 0.0 (0.0/0.5)c 0.4 (0.9/1.0)c 0.3 (0.0/0.7)d 0.0388 
Fusobacteriaceae 0.1 (0.0/0.5)c 0.8 (0.0/1.9)c 0.2 (0.1/1.1)d 0.0128 
Veillonellaceae 0.1 (0.0/0.9) 0.2 (0.0/13.6) 0.1 (0.0/2.1) 0.0626 
Streptococcaceae 0.1 (0.0/18.2) 0.0 (0.0/0.2) 0.0 (0.0/0.2) 0.7148 
Enterobacteriaceae 0.0 (0.0/0.0) 0.0 (0.0/0.0) 0.0 (0.0/0.0) 0.5404 
Genusb     
Clostridium 19.3 (11.0/32.9) 34.9 (16.6/39.3) 23.9 (8.6/39.6) 0.1603 
Ruminococcus 17.1 (9.5/23.7) 18.1 (8.7/25.4) 14.8 (5.6/26.4) 0.9139 
Dorea 6.8 (4.4/11.8) 5.8 (3.7/17.5) 7.2 (5.3/9.4) 0.9200 
Roseburia 5.1 (2.0/6.7)c 4.5 (2.6/8.6)d 3.3 (1.4/5.7)c,d 0.0183 
Turicibacter 3.0 (0.2/9.9) 1.9 (0.5/7.2) 1.9 (0.4/9.7) 0.7788 
Megamonas 0.0 (0.0/0.7) 0.1 (0.0/12.4) 0.1 (0.0/1.9) 0.1102 
Faecalibacterium 0.3 (0.1/5.1) 0.3 (0.0/6.4) 0.3 (0.0/0.5) 0.9770 
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Papillibacter 0.0 (0.0/0.1) 0.0 (0.0/0.4) 0.0 (0.0/0.1) 0.7979 
Prevotella 0.0 (0.0/0.4) 0.4 (0.0/3.2) 0.1 (0.0/0.5) 0.1522 
Lactobacillus 0.0 (0.0/0.3) 0.0 (0.0/0.1) 0.0 (0.0/0.0) 0.5308 
Sporobacter 0.0 (0.0/0.1) 0.1 (0.0/0.2) 0.0 (0.0/0.1) 0.1324 
Fusobacterium 0.1 (0.0/0.5)c 0.8 (0.0/1.9)c 0.2 (0.1/1.1)d 0.0128 
Allobaculum 0.6 (0.0/1.6) 0.8 (0.0/1.7) 0.2 (0.0/1.2) 0.3281 
Collinsella 1.3 (0.6/2.6) 1.7 (0.9/3.9) 0.7 (0.4/2.0) 0.1482 
Coprobacillus 0.1 (0.0/2.0) 0.1 (0.0/1.7) 0.0 (0.0/0.9) 0.5488 
Catenibacterium 0.1 (0.0/4.1) 0.5 (0.0/8.9) 0.4 (0.0/3.0) 0.9683 
Eubacterium 0.0 (0.0/0.5)c 0.4 (0.1/1.0)c 0.3 (0.0/0.7)d 0.0388 
Streptococcus 0.0 (0.0/16.2) 0.0 (0.0/0.2) 0.0 (0.0/0.2) 0.9753 
Bacteroides 0.0 (0.0/0.8) 0.1 (0.0/1.1) 0.1 (0.0/0.3) 0.6065 
Enterococcus 0.0 (0.0/0.1) 0.2 (0.0/0.5) 0.0 (0.0/2.7) 0.2319 
 
 
 
A total of 87,737 pyrosequencing tags were evaluated at baseline (BL), 56,852 at day 5 
of feeding the synbiotic (Day 5) and 57,053 after two days of discontinuation of 
treatment (Day 23).  
a P values in this table are not adjusted for falsely rejected null hypotheses. After 
adjustment, none of these P values were found to be lower than the Benjamin-Hochberg 
critical values, suggesting that the significant P values (P<0.05) are rejecting the null 
hypothesis that all three time points are equal when this is true (Type I error). 
b Clostridium, Ruminococcus, Dorea, Roseburia and Turicibacter were the only bacterial 
genera that were detected at all time points in all the subjects. The rest of the genera in 
this table were found in at least 2 time points in at least the half of the subjects. The 
remaining 56 genera found were only detected sporadically across subjects and therefore 
are not included in this table. 
c,d  Same letter indicates a statistically significant difference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 129
Supplementary Table A3 Oligonucleotides used for quantitative real-time PCR (qPCR) 
assays and fluorescent in situ hybridization (FISH). 
 
qPCR 
primers/probe 
Sequence (5’- 3’) Target Annealing 
(°C) 
Reference 
UniF CCTACGGGAGGCAGCAG All bacteria 59 Muyzer et 
al., 1993 
UniR ATTACCGCGGCTGCTGG    
EncocF CCCTTATTGTTAGTTGCCATCATT Enterococcus 61 Malinen et 
al., 2005 
EncocR ACTCGTTGTACTTCCCATTGT    
LacF AGCAGTAGGGAATCTTCCA Lactobacillus  58 Malinen et 
al., 2005 
LacR CACCGCTACACATGGAG    
BactF GGTGTCGGCTTAAGTGCCAT Bacteroides/Prevotella/ 
Porphyromonas  
55 Malinen et 
al., 2005 
BactR CGGACGTAAGGGCCGTGC    
Firm350f GGCAGCAGTRGGGAATCTTC Firmicutes 60 Muhling et 
al., 2008 
Firm814r ACACYTAGYACTCATCGTTT    
Gamma395F CMATGCCGCGTGTGTGAA γ Proteobacteria 69 Muhling et 
al., 2008 
Gamma871R ACTCCCCAGGCGGTCDACTTA    
BifF TCGCGTCYGGTGTGAAAG Bifidobacterium 60 Malinen et 
al., 2005 
BifR CCACATCCAGCRTCCAC    
FaecaF GAAGGCGGCCTACTGGGCAC Faecalibacterium 60 This study 
FaecaR GTGCAGGCGAGTTGCAGCCT    
RumiF ACTGAGAGGTTGAACGGCCA Family Ruminococcacea 59 This study 
RumiR CCTTTACACCCAGTAAWTCCGGA    
CPerf165F CGCATAACGTTGAAAGATGG C. perfringens 58 Wise & 
Siragusa, 
2005 
CPerf269R CCTTGGTAGGCCGTTACCC    
CPerf187F 
(probe) 
TCATCATTCAACCAAAGGAGCAATCC    
Forward TTGAGCGATTTACTTCGGTAAAGA C. difficile 61 Penders et 
al., 2005 
Reverse TGTACTGGCTCACCTTTGATATTCA    
probe CCACGCGTTACTCACCCGTCCG    
tcdB-F GGTATTACCTAATGCTCCAAATAG C. difficile toxin B gene 58 Houser et 
al., 2010 
tcdB-R TTTGTGCCATCATTTTCTAAGC    
tcdB-P (probe) ACCTGGTGTCCATCCTGTTTCCCA    
HelFa ACCAAGGCAATGACGGGTATC Helicobacter  60 Huijsdens 
et al., 2004 
HelR CGGAGTTAGCCGGTGCTTATT    
HelP (probe) AACCTTCATCCTCCACGCGGC    
FISH probes     
Eub 338 FAM-GCTGCCTCCCGTAGGAGT All bacteria 46 Amann et 
al., 1990 
Hel 274b Cy5-GGCCGGATACCCGTCATAGCCT Helicobacter spp. 46 Chan et 
al., 2005 
Hel 717b Cy5-AGGTCGCCTTCGCAATGAGTA    
 
aThis oligonucleotide does not match Helicobacter bilis nor Flexispira rapinni based on 
the Ribosomal Database Project (http://rdp.cme.msu.edu/). 
bThese oligonucleotides may also detect Wolinella spp. (Family Helicobacteriacea), 
based on the Ribosomal Database Project. 
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Supplementary Table A4 Median (interquartile range) proportions of pyrosequencing 
tags on Day 30 (Day -30) and Day 15 (Day -15) before starting omeprazole 
administration, Day 15 during omeprazole administration, and Day 30 after 
discontinuation of omeprazole administration in the stomach. P values were calculated 
by non-parametric Friedman’s tests. 
 
This table only shows those bacterial genera (and their respective phyla) that were 
identified in at least two time points in at least half the subjects. Only the genera 
Helicobacter and Curvibacter were detected in all animal subjects at all time points.  
a,b Same superscripts indicate statistically significant difference (p<0.05, Dunn’s 
multiple comparison). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Day -30 Day -15 Day 15 Day 30 p value 
Proteobacteria 99.6 (97.2-99.9) 99.5 (96.9-99.8) 97.0 (57.2-98.8) 99.4 (90.9-99.8) 0.0427 
Helicobacter 98.6 (96.6-98.9) 98.4 (96.0-99.0) 91.6 (53.6-97.4) 98.0 (90.2-99.4) 0.0336 
Curvibacter 0.5 (0.4-0.6) 0.7 (0.4-0.7) 0.5 (0.2-1.1) 0.3 (0.1-1.1) 0.7892 
Herbaspirillum 0.1 (0.0-0.2) 0.1 (0.1-0.1) 0.1 (0.0-0.2) 0.1 (0.0-0.1) 0.6823 
Neisseria 0.0 (0.0-0.0) 0.0 (0.0-0.1) 0.1 (0.0-0.4) 0.0 (0.0-0.0) 0.0151 
Actinobacillus 0.0 (0.0-0.0) 0.0 (0.0-0.2) 0.3 (0.2-3.4) 0.0 (0.0-0.1) 0.0272 
      
Firmicutes 0.3 (0.1-2.8) 0.2 (0.0-3.0) 1.5 (0.5-42.6) 0.4 (0.1-8.8) 0.0803 
Clostridium 0.0 (0.0-0.4) 0.0 (0.0-0.2) 0.1 (0.0-0.6) 0.0 (0.0-0.1) 0.1730 
Turicibacter 0.0 (0.0-0.7) 0.0 (0.0-0.1) 0.0 (0.0-0.2) 0.0 (0.0-8.7) 0.8243 
Lactobacillus 0.0 (0.0-0.1) 0.0 (0.0-1.6) 0.2 (0.0-28.6) 0.1 (0.0-0.3) 0.2140 
Prevotella 0.0 (0.0-0.0) 0.0 (0.0-0.1) 0.0 (0.0-0.4) 0.0 (0.0-0.0) 0.2683 
Streptococcus 0.0 (0.0-0.0) 0.0 (0.0-0.2) 0.3 (0.2-1.4)a 0.0 (0.0-0.0)a 0.0028 
      
Bacteroidetes 0.0 (0.0-0.1) 0.1 (0.0-0.2) 0.3 (0.0-1.7) 0.0 (0.0-0.1) 0.1351 
Porphyromonas 0.0 (0.0-0.0) 0.0 (0.0-0.1) 0.1 (0.0-0.3) 0.0 (0.0-0.0) 0.0338 
      
Fusobacteria 0.0 (0.0-0.0)a 0.0 (0.0-0.0) 0.2 (0.1-0.4)ab 0.0 (0.0-0.0)b 0.0006 
Fusobacterium 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.1 (0.0-0.2)a 0.0 (0.0-0.0)a 0.0017 
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Supplementary Table A5 Number of microscopic fields analyzed for each gender for 
FISH analyzes in the gastric (stomach) and the duodenal (duodenum) biopsies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Stomach 
 Day -30 Day -15 Day 15 Day 30 
males 185 155 145 151 
females 137 121 145 135 
  
 Duodenum 
males 106 111 136 124 
females 114 125 143 130 
 132
 
Supplementary Table A6 Median (interquartile range) proportions of pyrosequencing 
tags on Day 30 (Day -30) and Day 15 (Day -15) before initiation of omeprazole 
administration, Day 15 during omeprazole administration, and Day 30 after 
discontinuation of omeprazole treatment in the duodenum. P values come from the non-
parametric Friedman’s test. 
 
 Day -30 Day -15 Day 15 Day 30 p value 
Firmicutes 46.9 (21.2-86.4) 20.2 (9.6-88.2) 87.3 (40.4-98.8) 83.1 (16.0-98.6) 0.3266 
Streptococcus 0.4 (0.1-2.2) 0.8 (0.0-1.6) 0.9 (0.5-3.9) 0.3 (0.0-1.2) 0.1331 
Lactobacillus 1.7 (1.1-3.3) 0.5 (0.2-5.2) 5.3 (0.6-92.3) 2.6 (0.6-17.3) 0.4539 
Enterococcus 0.0 (0.0-0.1) 0.0 (0.0-0.1) 0.5 (0.1-0.9) 0.0 (0.0-0.4) 0.0137 
Clostridium 3.9 (0.7-18.1) 0.7 (0.4-2.3) 1.1 (0.1-17.4) 1.3 (0.4-27.5) 0.3691 
Eubacterium 0.4 (0.0-1.1) 0.6 (0.2-0.7) 0.1 (0.0-0.5) 0.2 (0.0-0.6) 0.7748 
Turicibacter 1.7 (0.0-33.6) 0.2 (0.0-1.6) 0.1 (0.0-0.2) 0.8 (0.4-40.5) 0.1261 
Peptostreptococcus 0.2 (0.0-1.6) 0.9 (0.2-1.5) 0.1 (0.0-1.4) 0.2 (0.0-1.8) 0.7876 
Gemella 0.4 (0.0-0.6) 0.1 (0.0-0.2) 0.3 (0.0-4.0) 0.2 (0.0-1.2) 0.3208 
Granulicatella 0.0 (0.0-1.2) 0.3 (0.1-0.6) 0.0 (0.0-0.3) 0.0 (0.0-0.1) 0.2457 
Roseburia 0.2 (0.0-1.9) 0.0 (0.0-0.4) 0.0 (0.0-0.2) 0.7 (0.1-0.8) 0.0529 
Ruminococcus 0.1 (0.0-0.4) 0.0 (0.0-0.2) 0.0 (0.0-0.0) 0.2 (0.0-0.2) 0.0576 
Allobaculum 0.1 (0.0-0.3) 0.2 (0.0-0.8) 0.1 (0.0-0.3) 0.0 (0.0-2.1) 0.6766 
Abiotrophia 0.2 (0.0-3.4) 0.6 (0.2-1.1) 0.6 (0.0-3.3) 0.0 (0.0-2.1) 0.6463 
Proteobacteria 21.2 (3.4-41.9) 15.9 (3.3-36.6) 5.6 (0.1-16.3) 11.1 (0.3-69.9) 0.1635 
Helicobacter 2.2 (0.1-4.3) 0.3 (0.0-1.0) 0.0 (0.0-0.0) 5.4 (0.0-64.6) 0.0287 
Achromobacter 0.5 (0.0-2.2) 1.1 (0.0-2.8) 0.0 (0.0-0.8) 0.1 (0.0-0.8) 0.3127 
Moraxella 0.4 (0.1-1.5) 0.3 (0.0-1.3) 0.0 (0.0-0.2) 0.1 (0.0-0.3) 0.1559 
Pasteurella 0.1 (0.0-0.4) 0.4 (0.0-0.7) 0.1 (0.0-0.7) 0.0 (0.0-0.1) 0.4180 
Neisseria 1.0 (0.0-2.3) 1.2 (0.1-1.5) 0.1 (0.0-0.8) 0.1 (0.0-0.5) 0.2598 
Bacteroidetes 6.9 (0.8-36.8) 23.7 (4.3-71.2) 1.6 (0.1-16.3) 2.2 (0.9-8.0) 0.4894 
Prevotella 2.4 (0.4-10.4) 7.1 (1.0-12.4) 1.5 (0.0-10.7) 1.1 (0.3-3.5) 0.2830 
Bacteroides 0.0 (0.0-1.5) 0.1 (0.0-0.2) 0.0 (0.0-0.1) 0.1 (0.0-0.1) 0.4753 
Bergeyella 0.2 (0.0-0.6) 0.3 (0.0-1.0) 0.0 (0.0-0.4) 0.2 (0.0-0.3) 0.6233 
Porphyromonas 2.3 (0.2-20.1) 10.1 (2.3-57.5) 0.0 (0.0-4.5) 0.5 (0.0-2.1) 0.0316 
Actinobacteria 1.4 (0.4-4.0) 1.2 (0.4-4.5) 0.1 (0.0-2.3) 0.5 (0.1-0.8) 0.6688 
Actinobacillus 1.0 (0.0-6.2) 6.1 (1.5-17.5) 2.4 (0.0-8.0) 0.4 (0.0-2.8) 0.0894 
Leucobacter 0.1 (0.0-1.0) 0.1 (0.0-0.7) 0.0 (0.0-1.1) 0.0 (0.0-0.2) 0.9098 
Actinomyces 0.3 (0.0-0.5) 0.1 (0.0-1.7) 0.0 (0.0-0.0) 0.0 (0.0-0.2) 0.0570 
Collinsella 0.3 (0.0-1.1) 0.0 (0.0-0.2) 0.0 (0.0-0.1) 0.0 (0.0-0.2) 0.1086 
Fusobacteria 0.2 (0.0-0.5) 0.2 (0.0-0.5) 0.0 (0.0-0.1) 0.0 (0.0-0.3) 0.3023 
Fusobacterium 0.2 (0.0-0.5) 0.2 (0.0-0.5) 0.0 (0.0-0.1) 0.0 (0.0-0.2) 0.1584 
 
This table only shows those bacterial genera (and their respective phyla) that were 
identified in at least two time points in at least half the subjects. Firmicutes and 
Proteobacteria were the only two phyla that were detected in all animal subjects at all 
time points. Only the bacterial genera Lactobacillus and Clostridium were detected in all 
animal subjects at all time points.  
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Supplementary Fig. A1. Dendrogram illustrating the phylogenetic clustering of the gastric (GB: gastric biopsy) and duodenal 
bacterial microbiota. Pyrosequencing was performed on all dogs (labeled A to H) on Day 30 (D-30) and Day 15 (D-15) before 
omeprazole administration, the last day of omeprazole administration (D15, bold), and 15 days after discontinuation of 
omeprazole administration (D30).  
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Supplementary Fig. A2. Dendrogram illustrating the phylogenetic clustering of the gastric microbiota. Pyrosequencing was 
performed on all dogs (labeled A to H) on Day 30 (D-30) and Day 15 (D-15) before omeprazole administration, the last day of 
omeprazole administration (D15, bold), and 15 days after discontinuation of omeprazole administration (D30).  
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Supplementary Fig. A3. Dendrogram illustrating the phylogenetic clustering of the duodenal microbiota. Pyrosequencing was 
performed on all eight dogs (labeled A to H) on Day 30 (D-30) and Day 15 (D-15) before omeprazole administration, the last 
day of omeprazole administration (D15, bold), and 15 days after discontinuation of omeprazole administration (D30).  
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Supplementary Fig. A4. Percentage of sequences in the male (left) and the female (right) dogs 
at the class Bacilli (a), order Lactobacillales (b), and Lactobacillus on Day 30 (Day -30) and Day 
15 (Day -15) before omeprazole administration, the last day of omeprazole administration (Day 
15), and on Day 30 after discontinuation of omeprazole administration. The line represents the 
median percentage of sequences and the letters identify the dogs. Notice that the y axis 
(percentage of sequences) is in a different scale for each gender.  
 
 
 
 
 
 137
 
 
 
 
 
 
 
Supplementary Fig. A5. Quantitative real-time PCR results for all fecal bacteria (a), Firmicutes 
(b), Ruminococcaceae (c), Faecalibacterium (d), Lactobacillus (e), the Bacteroides-Prevotella-
Porphyromonas group (f), gammaproteobacteria (g), and Bifidobacterium (h) on Day 30 (Day -
30) and Day 15 (Day -15) before omeprazole administration, during omeprazole administration 
on Day 15, and 15 days after completion of omeprazole administration (Day 30). Error bars 
represent the mean and the standard error. Horizontal brackets represent statistical significance 
(p<0.01). There was a significant interaction (p<0.05) between omeprazole administration and 
gender for all fecal bacteria (a), Faecalibacterium (d), the Bacteroides-Prevotella-
Porphyromonas group (f) and gammaproteobacteria (g). * Statistically significantly different 
(p<0.0001) than all other time points regardless of gender. Notice that the y axis is in a different 
scale for each bacterial group. 
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